U.S. patent application number 12/761759 was filed with the patent office on 2010-10-28 for novel serpentine transmembrane antigens expressed in human cancers and uses thereof.
Invention is credited to Daniel E. AFAR, Rene S. Hubert, Stephen Chappell Mitchell, Arthur B. Raitano, Douglas C. Saffran.
Application Number | 20100272742 12/761759 |
Document ID | / |
Family ID | 32072929 |
Filed Date | 2010-10-28 |
United States Patent
Application |
20100272742 |
Kind Code |
A1 |
AFAR; Daniel E. ; et
al. |
October 28, 2010 |
NOVEL SERPENTINE TRANSMEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCERS
AND USES THEREOF
Abstract
Described is a novel family of cell surface serpentine
transmembrane antigens. Two of the proteins in this family are
exclusively or predominantly expressed in the prostate, as well as
in prostate cancer, and thus members of this family have been
termed "STEAP" (Six Transmembrane Epithelial Antigens of the
Prostate). Four particular human STEAPs are described and
characterized herein. The prototype member of the STEAP family,
STEAP-1, appears to be a type IIIa membrane protein expressed
predominantly in prostate cells in normal human tissues.
Structurally, STEAP-1 is a 339 amino acid protein characterized by
a molecular topology of six transmembrane domains and intracellular
N- and C-termini, suggesting that it folds in a "serpentine" manner
into three extracellular and two intracellular loops. STEAP-1
protein expression is maintained at high levels across various
stages of prostate cancer. Moreover, STEAP-1 is highly
over-expressed in certain other human cancers.
Inventors: |
AFAR; Daniel E.; (Pacific
Palisades, CA) ; Hubert; Rene S.; (Los Angeles,
CA) ; Raitano; Arthur B.; (Los Angeles, CA) ;
Saffran; Douglas C.; (Los Angeles, CA) ; Mitchell;
Stephen Chappell; (Santa Monica, CA) |
Correspondence
Address: |
Arnold & Porter LLP (24126);Attn: SV Docketing Dept.
1400 Page Mill Road
Palo Alto
CA
94304
US
|
Family ID: |
32072929 |
Appl. No.: |
12/761759 |
Filed: |
April 16, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10857785 |
May 28, 2004 |
7727533 |
|
|
12761759 |
|
|
|
|
09455486 |
Dec 6, 1999 |
6833438 |
|
|
10857785 |
|
|
|
|
09323873 |
Jun 1, 1999 |
6329503 |
|
|
09455486 |
|
|
|
|
60091183 |
Jun 30, 1998 |
|
|
|
60087520 |
Jun 1, 1998 |
|
|
|
Current U.S.
Class: |
424/185.1 ;
435/375 |
Current CPC
Class: |
C07K 16/3069 20130101;
A61K 39/00 20130101; A61P 35/00 20180101; A61P 37/04 20180101; C07K
2317/34 20130101; A61P 43/00 20180101; A61K 38/00 20130101; A61K
2039/505 20130101; C07K 14/82 20130101; C12N 2799/027 20130101;
C07K 2319/00 20130101; G01N 33/57434 20130101; C07K 16/3038
20130101; Y10S 435/975 20130101; C07K 2319/30 20130101; C07K 14/705
20130101; C07K 16/30 20130101 |
Class at
Publication: |
424/185.1 ;
435/375 |
International
Class: |
A61K 39/00 20060101
A61K039/00; A61P 35/00 20060101 A61P035/00; A61P 37/04 20060101
A61P037/04; C12N 5/02 20060101 C12N005/02 |
Claims
1. A method for generating an immune response to STEAP-2 in a
mammal, comprising: a) contacting a cell of the mammal's immune
system with an immunogenic portion of: i) a protein having at least
90% homology to SEQ ID NO: 6; and/or ii) a nucleotide sequence that
encodes said protein; and b) inducing the cell to produce a
response to the protein.
2. The method of claim 1, wherein the protein having at least 90%
homology to SEQ ID NO: 6 comprises at least one T cell epitope or
at least one B cell epitope.
3. The method of claim 1, wherein the cell is a B cell.
4. The method of claim 3, wherein the response comprises generating
an antibody from the B cell that specifically binds to the protein
having at least 90% homology to SEQ ID NO: 6.
5. The method of claim 1, wherein the cell is a cytotoxic T
cell.
6. The method of claim 5, wherein the response comprises killing by
the cytotoxic T cell of an autologous cell that expresses the
protein having at least 90% homology to SEQ ID NO: 6.
7. The method of claim 1, wherein the cell is a helper T cell.
8. The method of claim 7 wherein the response comprises secretion
of cytokines from the helper T cell that facilitate the cytotoxic
activity of a cytotoxic T cell or the antibody producing activity
of a B cell.
9. The method of claim 4, wherein the antibody is
domain-specific.
10. The method of claim 1, wherein the protein is expressed in a
viral vector.
11. The method of claim 1, wherein the nucleotide sequence is
expressed in a viral vector.
12. The method of claim 11, wherein the nucleotide sequence is at
least 90% identical to SEQ ID NO: 7.
13. The method of claim 11, wherein the nucleotide sequence is SEQ
ID NO: 7.
14. A method for inducing a cellular immune response in a subject
to a protein having at least 90% homology to SEQ ID NO: 6 in a
subject having a cancer expressing STEAP-2 protein, comprising
administering to the subject a STEAP-2 protein or fragment thereof,
or a STEAP-2 antigen presenting cell.
15. The method of claim 14, wherein the cancer is a cancer set
forth in Table I.
16. The method of claim 14, wherein the step of administering
generates a humoral immune response.
17. The method of claim 14, wherein the STEAP-2 antigen presenting
cell is a dendritic cell.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of U.S. patent application
Ser. No. 10/857,785, filed May 28, 2004, which is a continuation of
U.S. patent application Ser. No. 09/455,486, filed Dec. 6, 1999,
now issued as U.S. Pat. No. 6,833,438 on Dec. 21, 2004, which is a
continuation-in-part of U.S. patent application Ser. No.
09/323,873, filed Jun. 1, 1999, now issued as U.S. Pat. No.
6,329,503 on Dec. 11, 2001, which claims the benefit of U.S.
Provisional Application No. 60/091,183, filed Jun. 30, 1998 and
U.S. Provisional Application No. 60/087,520, filed Jun. 1, 1998.
This application relates to U.S. patent application Ser. No.
10/408,009, filed Apr. 4, 2003, U.S. patent application Ser. No.
10/856,109, filed May 28, 2004, now issued as U.S. Pat. No.
7,319,006 on Jan. 15, 2008, U.S. patent application Ser. No.
10/752,421, filed Jan. 5, 2004, now issued as U.S. Pat. No.
7,455,991 on Nov. 25, 2008, U.S. patent application Ser. No.
11/546,008, filed Oct. 10, 2006, now issued as U.S. Pat. No.
7,485,299 on Feb. 3, 2009, U.S. patent application Ser. No.
11/647,988, filed Dec. 29, 2006, now abandoned, U.S. patent
application Ser. No. 10/407,484, filed Apr. 4, 2003, now abandoned,
U.S. patent application Ser. No. 11/588,203, filed Oct. 25, 2006,
now issued as U.S. Pat. No. 7,622,569 on Nov. 24, 2009, U.S.
Provisional Application No. 60/370,387, filed Apr. 5, 2002, U.S.
Provisional Application No. 60/435,480, filed Dec. 20, 2002, U.S.
patent application Ser. No. 10/455,822, filed Jun. 4, 2003, now
abandoned, U.S. patent application Ser. No. 10/862,182, filed Jun.
4, 2004, now abandoned, U.S. patent application Ser. No.
11/068,859, filed Feb. 28, 2005, now abandoned, U.S. patent
application Ser. No. 11/526,183, filed Sep. 22, 2006, U.S.
Provisional Application No. 60/296,656, filed Jun. 6, 2001, U.S.
patent application Ser. No. 10/165,044, filed Jun. 6, 2002, now
abandoned, U.S. patent application Ser. No. 10/753,195, filed Jan.
6, 2004, and U.S. patent application Ser. No. 11/542,758, filed
Oct. 3, 2006. The contents of the applications listed in this
paragraph are fully incorporated by reference herein.
FIELD OF THE INVENTION
[0002] The invention described herein relates to a family of novel
genes and their encoded proteins and tumor antigens, termed STEAPs,
and to diagnostic and therapeutic methods and compositions useful
in the management of various cancers, particularly including
prostate cancer, colon cancer, bladder cancer, ovarian cancer and
pancreatic cancer.
BACKGROUND OF THE INVENTION
[0003] Cancer is the second leading cause of human death next to
coronary disease. Around the world, millions of people die from
cancer every year. In the United States alone, cancer causes the
death of well over a half-million people each year, with some 1.4
million new cases diagnosed per year. While deaths from heart
disease have been declining significantly, those resulting from
cancer generally are on the rise. In the early part of the next
century, cancer is predicted to become the leading cause of
death.
[0004] Worldwide, several cancers stand out as the leading killers.
In particular, carcinomas of the lung, prostate, breast, colon,
pancreas, and ovary represent the leading causes of cancer death.
These and virtually all other carcinomas share a common lethal
feature. With very few exceptions, metastatic disease from a
carcinoma is fatal. Moreover, even for those cancer patients who
initially survive their primary cancers, common experience has
shown that their lives are dramatically altered. Many cancer
patients experience strong anxieties driven by the awareness of the
potential for recurrence or treatment failure. Many cancer patients
experience physical debilitations following treatment.
[0005] Generally speaking, the fundamental problem in the
management of the deadliest cancers is the lack of effective and
non-toxic systemic therapies. Molecular medicine, still very much
in its infancy, promises to redefine the ways in which these
cancers are managed. Unquestionably, there is an intensive
worldwide effort aimed at the development of novel molecular
approaches to cancer diagnosis and treatment. For example, there is
a great interest in identifying truly tumor-specific genes and
proteins that could be used as diagnostic and prognostic markers
and/or therapeutic targets or agents. Research efforts in these
areas are encouraging, and the increasing availability of useful
molecular technologies has accelerated the acquisition of
meaningful knowledge about cancer. Nevertheless, progress is slow
and generally uneven.
[0006] Recently, there has been a particularly strong interest in
identifying cell surface tumor-specific antigens which might be
useful as targets for various immunotherapeutic or small molecule
treatment strategies. A large number of such cell-surface antigens
have been reported, and some have proven to be reliably associated
with one or more cancers. Much attention has been focused on the
development of novel therapeutic strategies which target these
antigens. However, few truly effective immunological cancer
treatments have resulted.
[0007] The use of monoclonal antibodies to tumor-specific or
over-expressed antigens in the treatment of solid cancers is
instructive. Although antibody therapy has been well researched for
some 20 years, only very recently have corresponding
pharmaceuticals materialized. One example is the humanized
anti-HER2/neu monoclonal antibody, Herceptin, recently approved for
use in the treatment of metastatic breast cancers overexpressing
the HER2/neu receptor. Another is the human/mouse chimeric
anti-CD20/B cell lymphoma antibody, Rituxan, approved for the
treatment of non-Hodgkin's lymphoma. Several other antibodies are
being evaluated for the treatment of cancer in clinical trials or
in pre-clinical research, including a fully human IgG2 monoclonal
antibody specific for the epidermal growth factor receptor (Yang et
al., 1999, Cancer Res. 59: 1236). Evidently, antibody therapy is
finally emerging from a long embryonic phase. Nevertheless, there
is still a very great need for new, more-specific tumor antigens
for the application of antibody and other biological therapies. In
addition, there is a corresponding need for tumor antigens which
may be useful as markers for antibody-based diagnostic and imaging
methods, hopefully leading to the development of earlier diagnosis
and greater prognostic precision.
[0008] As discussed below, the management of prostate cancer serves
as a good example of the limited extent to which molecular biology
has translated into real progress in the clinic. With limited
exceptions, the situation is more or less the same for the other
major carcinomas mentioned above.
[0009] Worldwide, prostate cancer is the fourth most prevalent
cancer in men. In North America and Northern Europe, it is by far
the most common male cancer and is the second leading cause of
cancer death in men. In the United States alone, well over 40,000
men die annually of this disease, second only to lung cancer.
Despite the magnitude of these figures, there is still no effective
treatment for metastatic prostate cancer. Surgical prostatectomy,
radiation therapy, hormone ablation therapy, and chemotherapy
remain as the main treatment modalities. Unfortunately, these
treatments are clearly ineffective for many. Moreover, these
treatments are often associated with significant undesirable
consequences.
[0010] On the diagnostic front, the serum PSA assay has been a very
useful tool. Nevertheless, the specificity and general utility of
PSA is widely regarded as lacking in several respects. Neither PSA
testing, nor any other test nor biological marker has been proven
capable of reliably identifying early-stage disease. Similarly,
there is no marker available for predicting the emergence of the
typically fatal metastatic stage of the disease. Diagnosis of
metastatic prostate cancer is achieved by open surgical or
laparoscopic pelvic lymphadenectomy, whole body radionuclide scans,
skeletal radiography, and/or bone lesion biopsy analysis. Clearly,
better imaging and other less invasive diagnostic methods offer the
promise of easing the difficulty those procedures place on a
patient, as well as improving therapeutic options. However, until
there are prostate tumor markers capable of reliably identifying
early-stage disease, predicting susceptibility to metastasis, and
precisely imaging tumors, the management of prostate cancer will
continue to be extremely difficult. Accordingly, more specific
molecular tumor markers are clearly needed in the management of
prostate cancer.
[0011] There are some known markers which are expressed
predominantly in prostate, such as prostate specific membrane
antigen (PSM), a hydrolase with 85% identity to a rat
neuropeptidase (Carter et al., 1996, Proc. Natl. Acad. Sci. USA 93:
749; Bzdega et al., 1997, J. Neurochem. 69: 2270). However, the
expression of PSM in small intestine and brain (Israeli et al.,
1994, Cancer Res. 54: 1807), as well its potential role in
neuropeptide catabolism in brain, raises concern of potential
neurotoxicity with anti-PSM therapies. Preliminary results using an
Indium-111 labeled, anti-PSM monoclonal antibody to image recurrent
prostate cancer show some promise (Sodee et al., 1996, Clin Nuc Med
21: 759-766). More recently identified prostate cancer markers
include PCTA-1 (Su et al., 1996, Proc. Natl. Acad. Sci. USA 93:
7252) and prostate stem cell antigen (PSCA) (Reiter et al., 1998,
Proc. Natl. Acad. Sci. USA 95: 1735). PCTA-1, a novel galectin, is
largely secreted into the media of expressing cells and may hold
promise as a diagnostic serum marker for prostate cancer (Su et
al., 1996). PSCA, a GPI-linked cell surface molecule, was cloned
from LAPC-4 cDNA and is unique in that it is expressed primarily in
basal cells of normal prostate tissue and in cancer epithelia
(Reiter et al., 1998). Vaccines for prostate cancer are also being
actively explored with a variety of antigens, including PSM and
PSA.
SUMMARY OF THE INVENTION
[0012] The present invention relates to a novel family of cell
surface serpentine transmembrane antigens. Two of the proteins in
this family are exclusively or predominantly expressed in the
prostate, as well as in prostate cancer, and thus members of this
family have been termed "STEAP" (Six Transmembrane Epithelial
Antigen of the Prostate). Four particular human STEAPs are
described and characterized herein. The human STEAPs exhibit a high
degree of structural conservation among them but show no
significant structural homology to any known human proteins.
[0013] The prototype member of the STEAP family, STEAP-1, appears
to be a type IIIa membrane protein expressed predominantly in
prostate cells in normal human tissues. Structurally, STEAP-1 is a
339 amino acid protein characterized by a molecular topology of six
transmembrane domains and intracellular N- and C-termini,
suggesting that it folds in a "serpentine" manner into three
extracellular and two intracellular loops. STEAP-1 protein
expression is maintained at high levels across various stages of
prostate cancer. Moreover, STEAP-1 is highly over-expressed in
certain other human cancers. In particular, cell surface expression
of STEAP-1 has been definitively confirmed in a variety of prostate
and prostate cancer cells, bladder cancer cells and colon cancer
cells. These characteristics indicate that STEAP-1 is a specific
cell-surface tumor antigen expressed at high levels in prostate,
bladder, colon, and other cancers.
[0014] A second member of the family, STEAP-2, is a 454 amino acid
protein with a predicted molecular topology similar to that of
STEAP-1. STEAP-2, like STEAP-1, is prostate-specific in normal
human tissues and is also expressed in prostate cancer. Alignment
of the STEAP-2 and STEAP-1 ORFs shows 54.9% identity over a 237
amino acid residue overlap, and the locations of the six putative
transmembrane domains in STEAP-2 coincide with the locations of the
transmembrane domains in STEAP-1 (FIG. 11A).
[0015] STEAP-3 and STEAP-4 are also described herein. These are
also structurally related, and show unique expression profiles. In
particular, STEAP-3 and STEAP-4 appear to show a different tissue
restriction patterns. An amino acid sequence alignment of all four
STEAPs is shown in FIG. 11A.
[0016] The invention provides polynucleotides corresponding or
complementary to all or part of the STEAP genes, mRNAs, and/or
coding sequences, preferably in isolated form, including
polynucleotides encoding STEAP proteins and fragments thereof, DNA,
RNA, DNA/RNA hybrid, and related molecules, polynucleotides or
oligonucleotides complementary to the STEAP genes or mRNA sequences
or parts thereof, and polynucleotides or oligonucleotides which
hybridize to the STEAP genes, mRNAs, or to STEAP-encoding
polynucleotides. Also provided are means for isolating cDNAs and
the genes encoding STEAPs. Recombinant DNA molecules containing
STEAP polynucleotides, cells transformed or transduced with such
molecules, and host-vector systems for the expression of STEAP gene
products are also provided. The invention further provides STEAP
proteins and polypeptide fragments thereof. The invention further
provides antibodies that bind to STEAP proteins and polypeptide
fragments thereof, including polyclonal and monoclonal antibodies,
murine and other mammalian antibodies, chimeric antibodies,
humanized and fully human antibodies, and antibodies labeled with a
detectable marker, and antibodies conjugated to radionuclides,
toxins or other therapeutic compositions. The invention further
provides methods for detecting the presence of STEAP
polynucleotides and proteins in various biological samples, as well
as methods for identifying cells that express a STEAP. The
invention further provides various therapeutic compositions and
strategies for treating prostate cancer, including particularly,
antibody, vaccine and small molecule therapy.
BRIEF DESCRIPTION OF THE FIGURES
[0017] FIG. 1. STEAP-1 structure. 1A-1-1A-2: Nucleotide and deduced
amino acid sequences of STEAP-1 (8P1B4) clone 10 cDNA (SEQ ID NOS.
1 and 2, respectively). The start Methionine is indicated in bold
at amino acid residue position 1 and six putative transmembrane
domains are indicated in bold and are underlined. 1B: Schematic
representation of STEAP-1 transmembrane orientation; amino acid
residues bordering the predicted extracellular domains are
indicated and correspond to the numbering scheme of FIG. 1A. 1C:
G/C rich 5' non-coding sequence of the STEAP-1 gene as determined
by overlapping sequences of clone 10 and clone 3 (SEQ ID NO:3).
[0018] FIG. 2. Predominant expression of STEAP-1 in prostate
tissue. First strand cDNA was prepared from 16 normal tissues, the
LAPC xenografts (4AD, 4AI and 9AD) and HeLa cells. Normalization
was performed by PCR using primers to actin and GAPDH.
Semi-quantitative PCR, using primers derived from STEAP-1 (8P1D4)
cDNA (FIG. 1A), shows predominant expression of STEAP-1 in normal
prostate and the LAPC xenografts. The following primers were used
to amplify STEAP-1:
TABLE-US-00001 8P1D4.1 5'ACTTTGTTGATGACCAGGATTGGA 3' (SEQ ID NO:
14) 8P1D4.2 5'CAGAACTTCAGCACACACAGGAAC 3' (SEQ ID NO: 15)
[0019] FIG. 3. Northern blot analyses of STEAP-1 expression in
various normal human tissues and prostate cancer xenografts,
showing predominant expression of STEAP-1 in prostate tissue. FIG.
3A: Two multiple tissue northern blots (Clontech) were probed with
a full length STEAP cDNA clone 10 (FIG. 1A; SEQ ID NO: 1). Size
standards in kilobases (kb) are indicated on the side. Each lane
contains 2 .mu.g of mRNA that was normalized by using a
.beta.-actin probe. FIG. 3B: Multiple tissue RNA dot blot
(Clontech, Human Master Blot cat#7770-1) probed with STEAP-1 cDNA
clone 10 (FIG. 1A; SEQ ID NO: 1), showing approximately five-fold
greater expression in prostate relative to other tissues with
significant detectable expression.
[0020] FIG. 4A-4B. Nucleotide sequence (SEQ ID NO: 4) of STEAP-1
GTH9 clone corresponding to the 4 kb message on northern blots
(FIG. 3A). The sequence contains an intron of 2399 base pairs
relative to the STEAP-1 clone 10 sequence of FIG. 1A; coding
regions are nucleotides 96-857 and 3257-3510 (indicated in bold).
The start ATG is in bold and underlined, the STOP codon is in bold
and underlined, and the intron-exon boundaries are underlined.
[0021] FIG. 5. Expression of STEAP-1 in prostate and multiple
cancer cell lines and prostate cancer xenografts. Xenograft and
cell line filters were prepared with 10 .mu.g of total RNA per
lane. The blots were analyzed using the STEAP-1 clone 10 as probe.
All RNA samples were normalized by ethidium bromide staining and
subsequent analysis with a .beta.-actin probe. FIG. 5A: Expression
in various cancer cell lines and xenografts and prostate. Lanes as
follows: (1) PrEC cells, (2) normal prostate tissue, (3) LAPC-4 AD
xenograft, (4) LAPC-4 AI xenograft, (5) LAPC-9 AD xenograft, (6)
LAPC-9 AI xenograft, (7) LNCaP cells, (8) PC-3 cells, (9) DU145
cells, (10) PANC-1 cells, (11) BxPC-3 cells, (12) HPAC cells, (13)
Capan-1 cells, (14) CACO-2 cells, (15) LOVO cells, (16) T84 cells,
(17) COLO-205 cells, (18) KCL-22 cells (acute lymphocytic leukemia,
ALL), (19) HT1197 cells, (20) SCABER cells, (21) UM-UC-3 cells,
(22) TCCSUP cells, (23) J82 cells, (24) 5637 cells, (25) RD-ES
cells (Ewing sarcoma, EWS), (26) CAMA-1 cells, (27) DU4475 cells,
(28) MCF-7 cells, (29) MDA-MB-435s cells, (30) NTERA-2 cells, (31)
NCCIT cells, (32) TERA-1 cells, (33) TERA-2 cells, (34) A431 cells,
(35) HeLa cells, (36) OV-1063 cells, (37) PA-1 cells, (38) SW 626
cells, (39) CAOV-3 cells. FIG. 5B: The expression of STEAP-1 In
subcutaneously (sc) grown LAPC xenografts compared to the
expression in LAPC-4 and LAPC-9 xenografts grown in the tibia (it)
of mice.
[0022] FIG. 6. Western blot analysis of STEAP-1 protein expression
in tissues and multiple cell lines. Western blots of cell lysates
prepared from prostate cancer xenografts and cell lines were probed
with a polyclonal anti-STEAP-1 antibody preparation (see Example 3C
for details). The samples contain 20 .mu.g of protein and were
normalized with anti-Grb-2 probing of the Western blots.
[0023] FIG. 7. Cell surface biotinylation of STEAP-1. FIG. 7A: Cell
surface biotinylation of 293T cells transfected with vector alone
or with vector containing cDNA encoding 6His-tagged STEAP-1. Cell
lysates were immunoprecipitated with specific antibodies,
transferred to a membrane and probed with horseradish
peroxidase-conjugated streptavidin. Lanes 1-4 and 6 correspond to
immunoprecipitates from lysates prepared from STEAP-1 expressing
293T cells. Lanes 5 and 7 are immunoprecipitates from vector
transfected cells. The immunoprecipitations were performed using
the following antibodies: (1) sheep non-immune, (2) anti-Large T
antigen, (3) anti-CD71 (transferrin receptor), (4) anti-His, (5)
anti-His, (6) anti-STEAP-1, (7) anti-STEAP-1. FIG. 7B: Prostate
cancer (LNCaP, PC-3, DU145), bladder cancer (UM-UC-3, TCCSUP) and
colon cancer (LOVO, COLO) cell lines were either biotinylated (+)
or not (-) prior to lysis. Western blots of streptavidin-gel
purified proteins were probed with anti-STEAP-1 antibodies.
Molecular weight markers are indicated in kilodaltons (kD).
[0024] FIG. 8. Immunohistochemical analysis of STEAP-1 expression
using anti-STEAP-1 polyclonal antibody. Tissues were fixed in 10%
formalin and embedded in paraffin. Tissue sections were stained
using anti-STEAP-1 polyclonal antibodies directed towards the
N-terminal peptide. Samples include: (a) LNCaP cells probed in the
presence of N-terminal STEAP-1 peptide 1, (b) LNCaP plus non
specific peptide 2, (c) normal prostate tissue, (d) grade 3
prostate carcinoma, (e) grade 4 prostate carcinoma, (f) LAPC-9 AD
xenograft, (g) normal bladder, (h) normal colon. All images are at
400.times. magnification.
[0025] FIG. 9A-9D. Nucleotide and deduced amino acid sequences of
STEAP-2 (98P4B6) clone GTD3 cDNA (SEQ ID NOs: 5 and 6,
respectively). The start methionine and Kozak sequence are
indicated in bold, and the putative transmembrane domains are
underlined in bold. The 5' UTR exhibits a high GC content of
72%.
[0026] FIG. 10A-10E. Nucleotide and deduced amino acid sequences of
STEAP-3 (SEQ ID NOs: 7 and 8, respectively). Kozak region is
bolded. FIG. 10F. Nucleotide sequences (SEQ ID NOs: 9-12,
respectively) of dbest database entries corresponding to additional
STEAP family members obtained by searching with the protein
sequence of STEAP-1.
[0027] FIG. 11. Primary structural comparison of STEAP family
proteins.
[0028] FIG. 11A-1-11A-2. Amino acid sequence alignment of STEAP-1
(8P1D4 clone 10; SEQ ID NO: 2), STEAP-2 (98P4B6 clone GTD3; SEQ ID
NO: 6); STEAP-3/AI139607 (SEQ ID NO: 8); and STEAP-4/R80991 (SEQ ID
NO: 13) [STEAPs 1-4] using the PIMA 1.4 program; transmembrane
domains identified by the SOSUI program are in bold. PIMA maximal
linkage clustering results shown; identical residues shown in
bold.
[0029] FIG. 11B. Amino acid sequence alignment of STEAP-1 (8P1D4
clone 10; portion of SEQ ID NO: 2) and STEAP-2 (98P4B6 clone GTD3;
portion of SEQ ID NO: 6) sequences. The alignment was performed
using the SIM alignment program of the Baylor College of Medicine
Search Launcher Web site. Transmembrane domains are indicated in
boldface. The results show a 54.9% identity in a 237 residues
overlap (Score: 717.0; Gap frequency: 0.0%).
[0030] FIG. 11C. Amino acid sequence alignment of STEAP-1 (portion
of SEQ ID NO: 2) and STEAP-3 (98P4B6 clone GTD3; portion of SEQ ID
NO: 8) sequences. Identical residues indicated with asterisks. SIM
results: 40.9% identity in 264 residues overlap; Score: 625.0; Gap
frequency: 0.0%.
[0031] FIG. 11D. Amino acid sequence alignment of STEAP-2 (portion
of SEQ ID NO: 6) and STEAP-3 (98P4B6 clone GTD3; portion of SEQ ID
NO: 8) sequences. Identical residues indicated with asterisks. SIM
results: 47.8% identity in 416 residues overlap; Score: 1075.0; Gap
frequency: 0.2%.
[0032] FIG. 12. Expression of STEAP-3 mRNA in normal tissues by
Northern blot (FIG. 12A) and RT-PCR (FIG. 12B). For RT-PCR
analysis, first strand cDNA was prepared from 16 normal tissues.
Normalization was performed by PCR using primers to actin and
GAPDH. Semi-quantitative PCR, using primers to AI139607, shows
predominant expression of AI139607 in placenta and prostate after
25 cycles of amplification. The following primers were used to
amplify AI139607:
TABLE-US-00002 A1139607.1 5' TTAGGACAACTTGATCACCAGCA 3' (SEQ ID NO:
16) A1139607.2 5' TGTCCAGTCCAAACTGGGTTATTT 3' (SEQ ID NO: 17)
[0033] FIG. 13. Predominant expression of STEAP-4/R80991 in liver.
First strand cDNA was prepared from 16 normal tissues.
Normalization was performed by PCR using primers to actin and
GAPDH. Semi-quantitative PCR, using primers to R80991, shows
predominant expression of R80991 in liver after 25 cycles of
amplification. The following primers were used to amplify
R80991:
TABLE-US-00003 R80991.1 5'AGGGAGTTCAGCTTCGTTCAGTC 3' (SEQ ID NO:
18) R80991.2 5'GGTAGAACTTGTAGCGGCTCTCCT 3' (SEQ ID NO: 19)
[0034] FIG. 14. Predominant expression of STEAP-2 (98P4B6) in
prostate tissue. First strand cDNA was prepared from 8 normal
tissues, the LAPC xenografts (4AD, 4AI and 9AD) and HeLa cells.
Normalization was performed by PCR using primers to actin and
GAPDH. Semi-quantitative PCR, using primers to 98P4B6, shows
predominant expression of 98P4B6 in normal prostate and the LAPC
xenografts. The following primers were used to amplify STEAP-2:
TABLE-US-00004 98P4B6.1 5' GACTGAGCTGGAACTGGAATTTGT 3' (SEQ ID NO:
20) 98P4B6.2 5' TTTGAGGAGACTTCATCTCACTGG 3' (SEQ ID NO: 21)
[0035] FIG. 15. Expression of the prostate-specific STEAP-2/98P4B6
gene in normal tissues and in prostate cancer xenografts determined
by Northern blot analysis. Human normal tissue filters (A and B)
were obtained from CLONTECH and contain 2 .mu.g of mRNA per lane.
Xenograft filter (C) was prepared with 10 .mu.g of total RNA per
lane. The blots were analyzed using the SSH derived 98P4B6 clone as
probe. All RNA samples were normalized by ethidium bromide
staining.
[0036] FIG. 16. Expression of STEAP-2 in prostate and select cancer
cell lines as determined by Northern blot analysis. Xenograft and
cell line filters were prepared with 10 .mu.g total RNA per lane.
The blots were analyzed using an SSH derived 98P4B6 clone as probe.
All RNA samples were normalized by ethidium bromide staining.
[0037] FIG. 17. Chromosomal localization of STEAP family members.
The chromosomal localizations of the STEAP genes described herein
were determined using the GeneBridge4 radiation hybrid panel
(Research Genetics, Huntsville Ala.). The mapping for STEAP-2 and
AI139607 was performed using the Stanford G3 radiation hybrid panel
(Research Genetics, Huntsville Ala.).
[0038] FIG. 18. Schematic representation of Intron-Exon boundaries
within the ORF of the human STEAP-1 gene. A total of 3 Introns (i)
and 4 exons (e) were identified.
[0039] FIG. 19. Zooblot southern analysis of STEAP-1 gene in
various species. Genomic DNA was prepared from several different
organisms including human, monkey, dog, mouse, chicken and
Drosophila. Ten micrograms of each DNA sample was digested with
EcoRI, blotted onto nitrocellulose and probed with a STEAP-1 probe.
Size standards are indicated on the side in kilobases (kb).
[0040] FIG. 20. Southern blot analysis of mouse BAC with a STEAP-1
probe. DNA was prepared from human cells to isolate genomic DNA and
from a mouse BAC clone (12P11) that contains the mouse STEAP gene.
Each DNA sample was digested with EcoRI, blotted onto
nitrocellulose and probed. Eight micrograms of genomic DNA was
compared to 250 ng of mouse BAC DNA.
DETAILED DESCRIPTION OF THE INVENTION
[0041] Unless otherwise defined, all terms of art, notations and
other scientific terminology used herein are intended to have the
meanings commonly understood by those of skill in the art to which
this invention pertains. In some cases, terms with commonly
understood meanings are defined herein for clarity and/or for ready
reference, and the inclusion of such definitions herein should not
necessarily be construed to represent a substantial difference over
what is generally understood in the art. The techniques and
procedures described or referenced herein are generally well
understood and commonly employed using conventional methodology by
those skilled in the art, such as, for example, the widely utilized
molecular cloning methodologies described in Sambrook et al.,
Molecular Cloning: A Laboratory Manual 2nd. edition (1989) Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. As
appropriate, procedures involving the use of commercially available
kits and reagents are generally carried out in accordance with
manufacturer defined protocols and/or parameters unless otherwise
noted.
[0042] As used herein, the terms "advanced prostate cancer",
"locally advanced prostate cancer", "advanced disease" and "locally
advanced disease" mean prostate cancers which have extended through
the prostate capsule, and are meant to include stage C disease
under the American Urological Association (AUA) system, stage C1-C2
disease under the Whitmore-Jewett system, and stage T3-T4 and N+
disease under the TNM (tumor, node, metastasis) system. In general,
surgery is not recommended for patients with locally advanced
disease, and these patients have substantially less favorable
outcomes compared to patients having clinically localized
(organ-confined) prostate cancer. Locally advanced disease is
clinically identified by palpable evidence of induration beyond the
lateral border of the prostate, or asymmetry or induration above
the prostate base. Locally advanced prostate cancer is presently
diagnosed pathologically following radical prostatectomy if the
tumor invades or penetrates the prostatic capsule, extends into the
surgical margin, or invades the seminal vesicles.
[0043] As used herein, the terms "metastatic prostate cancer" and
"metastatic disease" mean prostate cancers which have spread to
regional lymph nodes or to distant sites, and are meant to include
stage D disease under the AUA system and stage T.times.N.times.M+
under the TNM system. As is the case with locally advanced prostate
cancer, surgery is generally not indicated for patients with
metastatic disease, and hormonal (androgen ablation) therapy is the
preferred treatment modality. Patients with metastatic prostate
cancer eventually develop an androgen-refractory state within 12 to
18 months of treatment initiation, and approximately half of these
patients die within 6 months thereafter. The most common site for
prostate cancer metastasis is bone. Prostate cancer bone metastases
are, on balance, characteristically osteoblastic rather than
osteolytic (i.e., resulting in net bone formation). Bone metastases
are found most frequently in the spine, followed by the femur,
pelvis, rib cage, skull and humerus. Other common sites for
metastasis include lymph nodes, lung, liver and brain. Metastatic
prostate cancer is typically diagnosed by open or laparoscopic
pelvic lymphadenectomy, whole body radionuclide scans, skeletal
radiography, and/or bone lesion biopsy.
[0044] As used herein, the term "polynucleotide" means a polymeric
form of nucleotides of at least 10 bases or base pairs in length,
either ribonucleotides or deoxynucleotides or a modified form of
either type of nucleotide, and is meant to include single and
double stranded forms of DNA.
[0045] As used herein, the term "polypeptide" means a polymer of at
least 8 amino acids. Throughout the specification, standard three
letter or single letter designations for amino acids are used.
[0046] As used herein, the terms "hybridize", "hybridizing",
"hybridizes" and the like, used in the context of polynucleotides,
are meant to refer to conventional hybridization conditions,
preferably such as hybridization in 50% formamide/6.times.SSC/0.1%
SDS/100 .mu.g/ml ssDNA, in which temperatures for hybridization are
above 37.degree. C. and temperatures for washing in
0.1.times.SSC/0.1% SDS are above 55.degree. C., and most preferably
to stringent hybridization conditions.
[0047] In the context of amino acid sequence comparisons, the term
"identity" is used to express the percentage of amino acid residues
at the same relative position which are the same. Also in this
context, the term "homology" is used to express the percentage of
amino acid residues at the same relative positions which are either
identical or are similar, using the conserved amino acid criteria
of BLAST analysis, as is generally understood in the art. Further
details regarding amino acid substitutions, which are considered
conservative under such criteria, are provided below.
[0048] Additional definitions are provided throughout the
subsections which follow.
Molecular and Biochemical Features of the STEAPs
[0049] The invention relates to a novel family of proteins, termed
STEAPs. Four STEAPs are specifically described herein by way of
structural, molecular and biochemical features. As is further
described in the Examples which follow, the STEAPs have been
characterized in a variety of ways. For example, analyses of
nucleotide coding and amino acid sequences were conducted in order
to identify conserved structural elements within the STEAP family.
Extensive RT-PCR and Northern blot analyses of STEAP mRNA
expression were conducted in order to establish the range of normal
and cancerous tissues expressing the various STEAP messages.
Western blot, immunohistochemical and flow cytometric analyses of
STEAP protein expression were conducted to determine protein
expression profiles, cell surface localization and gross molecular
topology of STEAP.
[0050] The prototype member of the STEAP family, STEAP-1, is a
six-transmembrane cell surface protein of 339 amino acids with no
identifiable homology to any known human protein. The cDNA
nucleotide and deduced amino acid sequences of human STEAP-1 are
shown in FIG. 1A. A gross topological schematic of the STEAP-1
protein integrated within the cell membrane is shown in FIG. 1B.
STEAP-1 expression is predominantly prostate-specific in normal
tissues. Specifically, extensive analysis of STEAP-1 mRNA and
protein expression in normal human tissues shows that STEAP-1
protein is predominantly expressed in prostate and, to a far
smaller degree, in bladder. STEAP-1 mRNA is also relatively
prostate specific, with only very low level expression detected in
a few other normal tissues. In cancer, STEAP-1 mRNA and protein is
consistently expressed at high levels in prostate cancer and during
all stages of the disease. STEAP-1 is also expressed in other
cancers. Specifically, STEAP-1 mRNA is expressed at very high
levels in bladder, colon, pancreatic, and ovarian cancer (as well
as other cancers). In addition, cell surface expression of STEAP-1
protein has been established in prostate, bladder and colon
cancers. Therefore, STEAP-1 has all of the hallmark characteristics
of an excellent therapeutic target for the treatment of certain
cancers, including particularly prostate, colon and bladder
carcinomas.
[0051] A second member of the family, STEAP-2, is a 454 amino acid
protein encoded by a distinct gene and having a predicted molecular
topology similar to that of STEAP-1. The cDNA nucleotide and
deduced amino acid sequences of STEAP-2 are shown in FIG. 9. Amino
acid alignment of the STEAP-1 and STEAP-2 sequences show a high
degree of structural conservation (54.9% identity over a 237 amino
acid residue overlap, and the locations of the six putative
transmembrane domains in STEAP-1 and STEAP-2 coincide (FIGS. 11A,
11B). Structural homology between these STEAP-1 and STEAP-2 is
highest in the regions spanned by the first putative extracellular
loop to the fifth transmembrane domain. However, some significant
structural differences between STEAP-1 and STEAP-2 are apparent.
For example, STEAP-2 exhibits a 205 a.a. long intracellular
N-terminus (compared to 69 a.a. in STEAP-1) and a short 4 a.a.
intracellular C-terminus (compared to 26 a.a. in STEAP-1). In
addition, both the STEAP-1 and STEAP-2 genes are located on
chromosome 7, but on different arms. These differences could imply
significant differences in function and/or interaction with
intracellular signaling pathways.
[0052] STEAP-2 is expressed only in normal prostate among human
tissues tested (FIGS. 14 and 15) and is also expressed in prostate
cancer (FIG. 15), and thus shows some similarity in expression
profile to STEAP-1. However, STEAP-2 exhibits a different mRNA
expression profile relative to STEAP-1 in prostate cancer samples
(compare FIGS. 3 and 15) and in other non-prostate cancers tested
(compare FIGS. 5 and 16). These differences in the expression
profiles of STEAP-1 and STEAP-2 suggest that they are
differentially regulated.
[0053] STEAP-3 and STEAP-4 appear to be closely related to both
STEAP-1 and STEAP-2 on a structural level, and both appear to be
transmembrane proteins as well. STEAP-3 is more related to STEAP-2
(47.8% identity) than to STEAP-1 (40.9% identity). STEAP-3 and
STEAP-4 show unique expression profiles. STEAP-3, for example,
appears to have an expression pattern which is predominantly
restricted to placenta and, to a smaller degree, expression is seen
in prostate but not in other normal tissues tested. STEAP-4 seems
to be expressed predominantly in liver by RT-PCR analysis. Neither
STEAP-3 nor STEAP-4 appear to be expressed in prostate cancer
xenografts which exhibit high level STEAP-1 and STEAP-2
expression.
[0054] Three of the four STEAPs described herein map to human
chromosome 7 (STEAP-1, -2 and 3). Interestingly, STEAP-1 maps
within 7p22 (7p22.3), a large region of allelic gain reported for
both primary and recurrent prostate cancers (Visakorpi et al., 1995
Cancer Res. 55: 342, Nupponen et al., 1998 American J. Pathol. 153:
141), suggesting that up-regulation of STEAP-1 in cancer might
include genomic mechanisms. In addition, both STEAP-2 and STEAP-3
locate to chromosome 7q21, suggesting that these two genes arose by
gene duplication.
[0055] The function of the STEAPs are not known. Other cell surface
molecules that contain six transmembrane domains include ion
channels (Dolly and Parcej, 1996 J Bioenerg Biomembr 28:231) and
water channels or aquaporins (Reizer et al., 1993 Crit Rev Biochem
Mol Biol 28:235). Structural studies show that both types of
molecules assemble into tetrameric complexes to form functional
channels (Christie, 1995, Clin Exp Pharmacol Physiol 22:944, Walz
et al., 1997 Nature 387:624, Cheng et al., 1997 Nature 387:627).
Immunohistochemical staining of STEAP-1 in the prostate gland seems
to be concentrated at the cell-cell boundaries, with less staining
detected at the luminal side. This may suggest a role for STEAP-1
in tight-junctions, gap junctions or cell adhesion. In order to
test these possibilities, xenopus oocytes (or other cells)
expressing STEAP may being analyzed using voltage-clamp and
patch-clamp experiments to determine if STEAP functions as an
ion-channel. Oocyte cell volume may also be measured to determine
if STEAP exhibits water channel properties. If STEAPs function as
channel or gap junction proteins, they may serve as excellent
targets for inhibition using, for example, antibodies, small
molecules, and polynucleotides capable of inhibiting expression or
function. The restricted expression pattern in normal tissue, and
the high levels of expression in cancer tissue suggest that
interfering with STEAP function may selectively kill cancer
cells.
[0056] Since the STEAP gene family is predominantly expressed in
epithelial tissue, it seems possible that the STEAP proteins
function as ion channels or gap junction proteins in epithelial
cell function. Ion channels have been implicated in proliferation
and invasiveness of prostate cancer cells (Lalani et al., 1997,
Cancer Metastasis Rev 16:29). Both rat and human prostate cancer
cells contain sub-population of cells with higher and lower
expression levels of sodium channels. Higher levels of sodium
channel expression correlate with more aggressive invasiveness in
vitro (Smith et al., 1998, FEBS Lett. 423:19). Similarly, it has
been shown that a specific blockade of sodium channels inhibits the
invasiveness of PC-3 cells in vitro (Laniado et al., 1997, Am. J.
Pathol. 150:1213), while specific inhibition of potassium channels
in LNCaP cells inhibited cell proliferation (Skryma et al., 1997,
Prostate 33:112). These reports suggest a role for ion channels in
prostate cancer and also demonstrate that small molecules that
inhibit ion channel function may interfere with prostate cancer
proliferation.
STEAP Polynucleotides
[0057] One aspect of the invention provides polynucleotides
corresponding or complementary to all or part of a STEAP gene,
mRNA, and/or coding sequence, preferably in isolated form,
including polynucleotides encoding a STEAP protein and fragments
thereof, DNA, RNA, DNA/RNA hybrid, and related molecules,
polynucleotides or oligonucleotides complementary to a STEAP gene
or mRNA sequence or a part thereof, and polynucleotides or
oligonucleotides which hybridize to a STEAP gene, mRNA, or to a
STEAP-encoding polynucleotide (collectively, "STEAP
polynucleotides"). As used herein, STEAP genes and proteins are
meant to include the STEAP-1, STEAP-2 and STEAP-3 genes and
proteins, and the gene and protein corresponding to GeneBank
Accession number R80991 (STEAP-4), and the genes and proteins
corresponding to other STEAP proteins and structurally similar
variants of the foregoing. Such other STEAP proteins and variants
will generally have coding sequences which are highly homologous to
the STEAP coding sequences provided herein, and preferably will
share at least about 50% amino acid identity and at least about 60%
amino acid homology (using BLAST criteria), more preferably sharing
70% or greater homology (using BLAST criteria).
[0058] The STEAP family member gene sequences described herein
encode STEAP proteins sharing unique highly conserved amino acid
sequence domains which distinguish them from other proteins.
Proteins which include one or more of these unique highly conserved
domains may be related to the STEAP family members or may represent
new STEAP proteins. Referring to FIG. 11A, which is an amino acid
sequence alignment of the full STEAP-1, STEAP-2, and STEAP-3
protein sequences as well as the partial STEAP-4 sequence, it is
clear that the STEAPs are closely related at the structural level.
Referring to FIG. 11B, which is an amino acid sequence alignment of
the full STEAP-1 and STEAP-2 protein sequences, close structural
conservation is apparent, particularly in the predicted
transmembrane domains. The STEAP-1 and STEAP-2 sequences share
54.9% identity over a 237 amino acid overlap. Additional amino acid
sequence alignments between the STEAPs are shown in FIGS. 11C and
11D. These alignments show that STEAP-1 and STEAP-3 are 40.9%
identical over a 264 amino acid region, while STEAP-2 and STEAP-3
are 47.8% identical over a 416 amino acid region.
[0059] A STEAP polynucleotide may comprise a polynucleotide having
the nucleotide sequence of human STEAP-1 as shown in FIG. 1A, the
nucleotide sequence of human STEAP-2 as shown in FIG. 9, the
nucleotide sequence of human STEAP-3 as shown in FIG. 10A, or the
nucleotide sequence of STEAP-4 as shown in FIG. 10B, or a sequence
complementary thereto, or a polynucleotide fragment of any of the
foregoing. Another embodiment comprises a polynucleotide which
encodes the human STEAP-1, STEAP-2, STEAP-3 or STEAP-4 protein
amino acid sequences, a sequence complementary thereto, or a
polynucleotide fragment of any of the foregoing. Another embodiment
comprises a polynucleotide which is capable of hybridizing under
stringent hybridization conditions to the human STEAP-1 cDNA shown
in FIG. 1A, the human STEAP-2 cDNA shown in FIG. 9, the human
STEAP-3 cDNA shown in FIG. 10A, or the STEAP-4 as shown in FIG.
10B, or to a polynucleotide fragment thereof.
[0060] Specifically contemplated are genomic DNA, cDNAs, ribozymes,
and antisense molecules, as well as nucleic acid molecules based on
an alternative backbone or including alternative bases, whether
derived from natural sources or synthesized. For example, antisense
molecules can be RNAs or other molecules, including peptide nucleic
acids (PNAs) or non-nucleic acid molecules such as phosphorothioate
derivatives, that specifically bind DNA or RNA in a base
pair-dependent manner. A skilled artisan can readily obtain these
classes of nucleic acid molecules using the STEAP polynucleotides
and polynucleotide sequences disclosed herein.
[0061] Further specific embodiments of this aspect of the invention
include primers and primer pairs, which allow the specific
amplification of the polynucleotides of the invention or of any
specific parts thereof, and probes that selectively or specifically
hybridize to nucleic acid molecules of the invention or to any part
thereof. Probes may be labeled with a detectable marker, such as,
for example, a radioisotope, fluorescent compound, bioluminescent
compound, a chemiluminescent compound, metal chelator or enzyme.
Such probes and primers can be used to detect the presence of a
STEAP polynucleotide in a sample and as a means for detecting a
cell expressing a STEAP protein. Examples of such probes include
polynucleotides comprising all or part of the human STEAP-1,
STEAP-2 and STEAP-3 cDNA sequences shown in FIGS. 1A, 9 and 10A,
respectively. Examples of primer pairs capable of specifically
amplifying STEAP mRNAs are also described in the Examples which
follow. As will be understood by the skilled person, a great many
different primers and probes may be prepared based on the sequences
provided in herein and used effectively to amplify and/or detect a
STEAP mRNA or an mRNA encoding a particular STEAP family
member.
[0062] As used herein, a polynucleotide is said to be "isolated"
when it is substantially separated from contaminant polynucleotides
which correspond or are complementary to genes other than the STEAP
gene or which encode polypeptides other than STEAP gene product or
fragments thereof. A skilled artisan can readily employ nucleic
acid isolation procedures to obtain an isolated STEAP
polynucleotide.
[0063] The STEAP polynucleotides of the invention are useful for a
variety of purposes, including but not limited to their use as
probes and primers for the amplification and/or detection of the
STEAP gene(s), mRNA(s), or fragments thereof; as reagents for the
diagnosis and/or prognosis of prostate cancer and other cancers; as
coding sequences capable of directing the expression of STEAP
polypeptides; as tools for modulating or inhibiting the expression
of the STEAP gene(s) and/or translation of the STEAP transcript(s);
and as therapeutic agents.
Methods for Isolating STEAP-Encoding Nucleic Acid Molecules
[0064] The STEAP cDNA sequences described herein enable the
isolation of other polynucleotides encoding STEAP gene product(s),
as well as the isolation of polynucleotides encoding STEAP gene
product homologues, alternatively spliced isoforms, allelic
variants, and mutant forms of the STEAP gene product. Various
molecular cloning methods that can be employed to isolate full
length cDNAs encoding a STEAP gene are well known (See, for
example, Sambrook, J. et al., Molecular Cloning: A Laboratory
Manual, 2d edition, Cold Spring Harbor Press, New York, 1989;
Current Protocols in Molecular Biology. Ausubel et al., Eds., Wiley
and Sons, 1995). For example, lambda phage cloning methodologies
may be conveniently employed, using commercially available cloning
systems (e.g., Lambda ZAP Express, Stratagene). Phage clones
containing STEAP gene cDNAs may be identified by probing with a
labeled STEAP cDNA or a fragment thereof. For example, in one
embodiment, the STEAP-1 cDNA (FIG. 1A) or a portion thereof can be
synthesized and used as a probe to retrieve overlapping and full
length cDNAs corresponding to a STEAP gene. Similarly, the STEAP-2
and STEAP-3 cDNA sequence may be employed. A STEAP gene may be
isolated by screening genomic DNA libraries, bacterial artificial
chromosome libraries (BACs), yeast artificial chromosome libraries
(YACs), and the like, with STEAP DNA probes or primers.
Recombinant DNA Molecules and Host-Vector Systems
[0065] The invention also provides recombinant DNA or RNA molecules
containing a STEAP polynucleotide, including but not limited to
phages, plasmids, phagemids, cosmids, YACs, BACs, as well as
various viral and non-viral vectors well known in the art, and
cells transformed or transfected with such recombinant DNA or RNA
molecules. As used herein, a recombinant DNA or RNA molecule is a
DNA or RNA molecule that has been subjected to molecular
manipulation in vitro. Methods for generating such molecules are
well known (see, for example, Sambrook et al, 1989, supra).
[0066] The invention further provides a host-vector system
comprising a recombinant DNA molecule containing a STEAP
polynucleotide within a suitable prokaryotic or eukaryotic host
cell. Examples of suitable eukaryotic host cells include a yeast
cell, a plant cell, or an animal cell, such as a mammalian cell or
an insect cell (e.g., a baculovirus-infectible cell such as an Sf9
cell). Examples of suitable mammalian cells include various
prostate cancer cell lines such LnCaP, PC-3, DU145, LAPC-4, TsuPr1,
other transfectable or transducible prostate cancer cell lines, as
well as a number of mammalian cells routinely used for the
expression of recombinant proteins (e.g., COS, CHO, 293, 293T
cells). More particularly, a polynucleotide comprising the coding
sequence of a STEAP may be used to generate STEAP proteins or
fragments thereof using any number of host-vector systems routinely
used and widely known in the art.
[0067] A wide range of host-vector systems suitable for the
expression of STEAP proteins or fragments thereof are available,
see for example, Sambrook et al., 1989, supra; Current Protocols in
Molecular Biology, 1995, supra). Preferred vectors for mammalian
expression include but are not limited to pcDNA 3.1 myc-His-tag
(Invitrogen) and the retroviral vector pSR.alpha.tkneo (Muller et
al., 1991, MCB 11:1785). Using these expression vectors, STEAP may
be preferably expressed in several prostate cancer and non-prostate
cell lines, including for example 293, 293T, rat-1, 3T3, PC-3,
LNCaP and TsuPr1. The host-vector systems of the invention are
useful for the production of a STEAP protein or fragment thereof.
Such host-vector systems may be employed to study the functional
properties of STEAP and STEAP mutations.
[0068] Proteins encoded by the STEAP genes, or by fragments
thereof, will have a variety of uses, including but not limited to
generating antibodies and in methods for identifying ligands and
other agents and cellular constituents that bind to a STEAP gene
product. Antibodies raised against a STEAP protein or fragment
thereof may be useful in diagnostic and prognostic assays, imaging
methodologies (including, particularly, cancer imaging), and
therapeutic methods in the management of human cancers
characterized by expression of a STEAP protein, such as prostate,
colon, breast, cervical and bladder carcinomas, ovarian cancers,
testicular cancers and pancreatic cancers. Various immunological
assays useful for the detection of STEAP proteins are contemplated,
including but not limited to various types of radioimmunoassays,
enzyme-linked immunosorbent assays (ELISA), enzyme-linked
immunofluorescent assays (ELIFA), immunocytochemical methods, and
the like. Such antibodies may be labeled and used as immunological
imaging reagents capable of detecting prostate cells (e.g., in
radioscintigraphic imaging methods). STEAP proteins may also be
particularly useful in generating cancer vaccines, as further
described below.
STEAP Proteins
[0069] Another aspect of the present invention provides various
STEAP proteins and polypeptide fragments thereof. As used herein, a
STEAP protein refers to a protein that has or includes the amino
acid sequence of human STEAP-1 as provided in FIG. 1A, human
STEAP-2 as provided in FIG. 9, human STEAP-3 as provided in FIG.
10A, the amino acid sequence of other mammalian STEAP homologues
(e.g., STEAP-4) and variants, as well as allelic variants and
conservative substitution mutants of these proteins that have STEAP
biological activity.
[0070] The STEAP proteins of the invention include those
specifically identified herein, as well as allelic variants,
conservative substitution variants and homologs that can be
isolated/generated and characterized without undue experimentation
following the methods outlined below. Fusion proteins which combine
parts of different STEAP proteins or fragments thereof, as well as
fusion proteins of a STEAP protein and a heterologous polypeptide
are also included. Such STEAP proteins will be collectively
referred to as the STEAP proteins, the proteins of the invention,
or STEAP. As used herein, the term "STEAP polypeptide" refers to a
polypeptide fragment or a STEAP protein of at least 8 amino acids,
preferably at least 10 amino acids.
[0071] A specific embodiment of a STEAP protein comprises a
polypeptide having the amino acid sequence of human STEAP-1 as
shown in FIG. 1A. Another embodiment of a STEAP protein comprises a
polypeptide containing the STEAP-2 amino acid sequence as shown in
FIG. 9. Another embodiment comprises a polypeptide containing the
STEAP-3 amino acid sequence of shown in FIG. 10A. Yet another
embodiment comprises a polypeptide containing the partial STEAP-4
amino acid sequence of shown in FIG. 11A.
[0072] In general, naturally occurring allelic variants of human
STEAP will share a high degree of structural identity and homology
(e.g., 90% or more identity). Typically, allelic variants of the
STEAP proteins will contain conservative amino acid substitutions
within the STEAP sequences described herein or will contain a
substitution of an amino acid from a corresponding position in a
STEAP homologue. One class of STEAP allelic variants will be
proteins that share a high degree of homology with at least a small
region of a particular STEAP amino acid sequence, but will further
contain a radical departure form the sequence, such as a
non-conservative substitution, truncation, insertion or frame
shift. Such alleles represent mutant STEAP proteins that typically
do not perform the same biological functions or do not have all of
the biological characteristics.
[0073] Conservative amino acid substitutions can frequently be made
in a protein without altering either the conformation or the
function of the protein. Such changes include substituting any of
isoleucine (I), valine (V), and leucine (L) for any other of these
hydrophobic amino acids; aspartic acid (D) for glutamic acid (E)
and vice versa; glutamine (O) for asparagine (N) and vice versa;
and serine (S) for threonine (T) and vice versa. Other
substitutions can also be considered conservative, depending on the
environment of the particular amino acid and its role in the
three-dimensional structure of the protein. For example, glycine
(G) and alanine (A) can frequently be interchangeable, as can
alanine (A) and valine (V). Methionine (M), which is relatively
hydrophobic, can frequently be interchanged with leucine and
isoleucine, and sometimes with valine. Lysine (K) and arginine (R)
are frequently interchangeable in locations in which the
significant feature of the amino acid residue is its charge and the
differing pKs of these two amino acid residues are not significant.
Still other changes can be considered "conservative" in particular
environments.
[0074] STEAP proteins may be embodied in many forms preferably in
isolated form. As used herein, a protein is said to be "isolated"
when physical, mechanical or chemical methods are employed to
remove the STEAP protein from cellular constituents that are
normally associated with the protein. A skilled artisan can readily
employ standard purification methods to obtain an isolated STEAP
protein. A purified STEAP protein molecule will be substantially
free of other proteins or molecules which impair the binding of
STEAP to antibody or other ligand. The nature and degree of
isolation and purification will depend on the intended use.
Embodiments of a STEAP protein include a purified STEAP protein and
a functional, soluble STEAP protein. In one form, such functional,
soluble STEAP proteins or fragments thereof retain the ability to
bind antibody or other ligand.
[0075] The invention also provides STEAP polypeptides comprising
biologically active fragments of the STEAP amino acid sequence,
such as a polypeptide corresponding to part of the amino acid
sequences for STEAP-1 as shown in FIG. 1A, STEAP-2 as shown in FIG.
9, STEAP-3 as shown in FIG. 10A, or STEAP-4 as shown in FIG. 11A.
Such polypeptides of the invention exhibit properties of a STEAP
protein, such as the ability to elicit the generation of antibodies
which specifically bind an epitope associated with a STEAP protein.
Polypeptides comprising amino acid sequences which are unique to a
particular STEAP protein (relative to other STEAP proteins) may be
used to generate antibodies which will specifically react with that
particular STEAP protein. For example, referring to the amino acid
alignment of the STEAP structures shown in FIGS. 11A-D, the skilled
artisan will readily appreciate that each molecule contains
stretches of sequence unique to its structure. These unique
stretches can be used to generate antibodies specific to a
particular STEAP. Similarly, regions of conserved sequence may be
used to generate antibodies that may bind to multiple STEAPs.
[0076] STEAP polypeptides can be generated using standard peptide
synthesis technology or using chemical cleavage methods well known
in the art based on the amino acid sequences of the human STEAP
proteins disclosed herein. Alternatively, recombinant methods can
be used to generate nucleic acid molecules that encode a
polypeptide fragment of a STEAP protein. In this regard, the
STEAP-encoding nucleic acid molecules described herein provide
means for generating defined fragments of STEAP proteins. STEAP
polypeptides are particularly useful in generating and
characterizing domain specific antibodies (e.g., antibodies
recognizing an extracellular or intracellular epitope of a STEAP
protein), in generating STEAP family member specific antibodies
(e.g., anti-STEAP-1, anti-STEAP 2 antibodies), identifying agents
or cellular factors that bind to a particular STEAP or STEAP
domain, and in various therapeutic contexts, including but not
limited to cancer vaccines. STEAP polypeptides containing
particularly interesting structures can be predicted and/or
identified using various analytical techniques well known in the
art, including, for example, the methods of Chou-Fasman,
Garnier-Robson, Kyte-Doolittle, Eisenberg, Karplus-Schultz or
Jameson-Wolf analysis, or on the basis of immunogenicity. Fragments
containing such structures are particularly useful in generating
subunit specific anti-STEAP antibodies or in identifying cellular
factors that bind to STEAP.
STEAP Antibodies
[0077] Another aspect of the invention provides antibodies that
bind to STEAP proteins and polypeptides. The most preferred
antibodies will selectively bind to a STEAP protein and will not
bind (or will bind weakly) to non-STEAP proteins and polypeptides.
Anti-STEAP antibodies that are particularly contemplated include
monoclonal and polyclonal antibodies as well as fragments
containing the antigen binding domain and/or one or more
complementarity determining regions of these antibodies. As used
herein, an antibody fragment is defined as at least a portion of
the variable region of the immunoglobulin molecule which binds to
its target, i.e., the antigen binding region.
[0078] For some applications, it may be desirable to generate
antibodies which specifically react with a particular STEAP protein
and/or an epitope within a particular structural domain. For
example, preferred antibodies useful for cancer therapy and
diagnostic imaging purposes are those which react with an epitope
in an extracellular region of the STEAP protein as expressed in
cancer cells. Such antibodies may be generated by using the STEAP
proteins described herein, or using peptides derived from predicted
extracellular domains thereof, as an immunogen. In this regard,
with reference to the STEAP-1 protein topological schematic shown
in FIG. 1B, regions in the extracellular loops between the
indicated transmembrane domains may be selected as used to design
appropriate immunogens for raising extracellular-specific
antibodies.
[0079] STEAP antibodies of the invention may be particularly useful
in prostate cancer therapeutic strategies, diagnostic and
prognostic assays, and imaging methodologies. The invention
provides various immunological assays useful for the detection and
quantification of STEAP and mutant STEAP proteins and polypeptides.
Such assays generally comprise one or more STEAP antibodies capable
of recognizing and binding a STEAP or mutant STEAP protein, as
appropriate, and may be performed within various immunological
assay formats well known in the art, including but not limited to
various types of radioimmunoassays, enzyme-linked immunosorbent
assays (ELISA), enzyme-linked immunofluorescent assays (ELIFA), and
the like. In addition, immunological imaging methods capable of
detecting prostate cancer are also provided by the invention,
including but limited to radioscintigraphic imaging methods using
labeled STEAP antibodies. Such assays may be clinically useful in
the detection, monitoring, and prognosis of prostate cancer,
particularly advanced prostate cancer.
[0080] The invention also provides various immunological assays
useful for the detection and quantification of STEAP and mutant
STEAP proteins and polypeptides. Such assays generally comprise one
or more STEAP antibodies capable of recognizing and binding a STEAP
or mutant STEAP protein, as appropriate, and may be performed
within various immunological assay formats well known in the art,
including but not limited to various types of radioimmunoassays,
enzyme-linked immunosorbent assays (ELISA), enzyme-linked
immunofluorescent assays (ELIFA), and the like. In addition,
immunological imaging methods capable of detecting prostate cancer
and other cancers expressing STEAP (e.g., breast cancer) are also
provided by the invention, including but limited to
radioscintigraphic imaging methods using labeled STEAP antibodies.
Such assays may be clinically useful in the detection, monitoring,
and prognosis of STEAP expressing cancers such as prostate
cancer.
[0081] STEAP antibodies may also be used in methods for purifying
STEAP and mutant STEAP proteins and polypeptides and for isolating
STEAP homologues and related molecules. For example, in one
embodiment, the method of purifying a STEAP protein comprises
incubating a STEAP antibody, which has been coupled to a solid
matrix, with a lysate or other solution containing STEAP under
conditions which permit the STEAP antibody to bind to STEAP;
washing the solid matrix to eliminate impurities; and eluting the
STEAP from the coupled antibody. Other uses of the STEAP antibodies
of the invention include generating anti-idiotypic antibodies that
mimic the STEAP protein.
[0082] Various methods for the preparation of antibodies are well
known in the art. For example, antibodies may be prepared by
immunizing a suitable mammalian host using a STEAP protein,
peptide, or fragment, in isolated or immunoconjugated form
(Antibodies: A Laboratory Manual, CSH Press, Eds., Harlow, and Lane
(1988); Harlow, Antibodies, Cold Spring Harbor Press, NY (1989)).
In addition, fusion proteins of STEAP may also be used, such as a
STEAP GST-fusion protein. In a particular embodiment, a GST fusion
protein comprising all or most of the open reading frame amino acid
sequence of a STEAP may be produced and used as an immunogen to
generate appropriate antibodies. In another embodiment, a STEAP
peptide may be synthesized and used as an immunogen. As described
in Example 5, below, the 15-mer STEAP peptide HSSKEKLRRERIKYC was
conjugated to keyhole limpet hemocyanin (KLH) and used to immunize
a rabbit. The resulting polyclonal antiserum specifically
recognized STEAP expressed in a recombinant mammalian expression
system.
[0083] In addition, naked DNA immunization techniques known in the
art may be used (with or without purified STEAP protein or STEAP
expressing cells) to generate an immune response to the encoded
immunogen (for review, see Donnelly et al., 1997, Ann. Rev.
Immunol. 15: 617-648).
[0084] The amino acid sequences of the STEAPs provided herein may
be used to select specific regions of the STEAP protein for
generating antibodies. For example, hydrophobicity and
hydrophilicity analyses of the STEAP amino acid sequence may be
used to identify hydrophilic regions in the STEAP structure.
Regions of the STEAP protein that show immunogenic structure, as
well as other regions and domains, can readily be identified using
various other methods known in the art, such as Chou-Fasman,
Garnier-Robson, Kyte-Doolittle, Eisenberg, Karplus-Schultz or
Jameson-Wolf analysis. Methods for the generation of STEAP
antibodies are further illustrated by way of the examples provided
herein.
[0085] Methods for preparing a protein or polypeptide for use as
immunogen and for preparing immunogenic conjugates of a protein
with a carrier such as BSA, KLH, or other carrier proteins are well
known in the art in some circumstances, direct conjugation using,
for example, carbodiimide reagents may be used; in other instances
linking reagents such as those supplied by Pierce Chemical Co.,
Rockford, Ill., may be effective. Administration of a STEAP
immunogen is conducted generally by injection over a suitable time
period and with use of a suitable adjuvant, as is generally
understood in the art. During the immunization schedule, titers of
antibodies can be taken to determine adequacy of antibody
formation.
[0086] STEAP monoclonal antibodies are preferred and may be
produced by various means well known in the art. For example,
immortalized cell lines which secrete a desired monoclonal antibody
may be prepared using the standard method of Kohler and Milstein or
modifications which effect immortalization of lymphocytes or spleen
cells, as is generally known. The immortalized cell lines secreting
the desired antibodies are screened by immunoassay in which the
antigen is the STEAP protein or STEAP fragment. When the
appropriate immortalized cell culture secreting the desired
antibody is identified, the cells may be expanded and antibodies
produced either from in vitro cultures or from ascites fluid.
[0087] The antibodies or fragments may also be produced, using
current technology, by recombinant means. Regions that bind
specifically to the desired regions of the STEAP protein can also
be produced in the context of chimeric or CDR grafted antibodies of
multiple species origin. Humanized or human STEAP antibodies may
also be produced and are preferred for use in therapeutic contexts.
Methods for humanizing murine and other non-human antibodies by
substituting one or more of the non-human antibody CDRs for
corresponding human antibody sequences are well known (see for
example, Jones et al., 1986, Nature 321: 522-525; Riechmnan et al.,
1988, Nature 332: 323-327; Verhoeyen et al., 1988, Science 239:
1534-1536). See also, Carter et al., 1993, Proc. Natl. Acad. Sci.
USA 89: 4285 and Sims et al., 1993, J. Immunol. 151: 2296. Methods
for producing fully human monoclonal antibodies include phage
display and transgenic methods (for review, see Vaughan et al.,
1998, Nature Biotechnology 16: 535-539).
[0088] Fully human STEAP monoclonal antibodies may be generated
using cloning technologies employing large human Ig gene
combinatorial libraries (i.e., phage display) (Griffiths and
Hoogenboom, Building an in vitro immune system: human antibodies
from phage display libraries. In: Protein Engineering of Antibody
Molecules for Prophylactic and Therapeutic Applications in Man.
Clark, M. (Ed.), Nottingham Academic, pp 45-64 (1993); Burton and
Barbas, Human Antibodies from combinatorial libraries. Id., pp
65-82). Fully human STEAP monoclonal antibodies may also be
produced using transgenic mice engineered to contain human
immunoglobulin gene loci as described in PCT Patent Application
WO98/24893, Kucherlapati and Jakobovits et al., published Dec. 3,
1997 (see also, Jakobovits, 1998, Exp. Opin. Invest. Drugs 7(4):
607-614). This method avoids the in vitro manipulation required
with phage display technology and efficiently produces high
affinity authentic human antibodies.
[0089] Reactivity of STEAP antibodies with a STEAP protein may be
established by a number of well known means, including Western
blot, immunoprecipitation, ELISA, and FACS analyses using, as
appropriate, STEAP proteins, peptides, STEAP-expressing cells or
extracts thereof.
[0090] A STEAP antibody or fragment thereof of the invention may be
labeled with a detectable marker or conjugated to a second
molecule. Suitable detectable markers include, but are not limited
to, a radioisotope, a fluorescent compound, a bioluminescent
compound, chemiluminescent compound, a metal chelator or an enzyme.
Further, bispecific antibodies specific for two or more STEAP
epitopes may be generated using methods generally known in the art.
Homodimeric antibodies may also be generated by cross-linking
techniques known in the art (e.g., Wolff et al., Cancer Res. 53:
2560-2565).
Methods for the Detection of STEAP
[0091] Another aspect of the present invention relates to methods
for detecting STEAP polynucleotides and STEAP proteins, as well as
methods for identifying a cell which expresses STEAP.
[0092] More particularly, the invention provides assays for the
detection of STEAP polynucleotides in a biological sample, such as
serum, bone, prostate, and other tissues, urine, semen, cell
preparations, and the like. Detectable STEAP polynucleotides
include, for example, a STEAP gene or fragments thereof, STEAP
mRNA, alternative splice variant STEAP mRNAs, and recombinant DNA
or RNA molecules containing a STEAP polynucleotide. A number of
methods for amplifying and/or detecting the presence of STEAP
polynucleotides are well known in the art and may be employed in
the practice of this aspect of the invention.
[0093] In one embodiment, a method for detecting a STEAP mRNA in a
biological sample comprises producing cDNA from the sample by
reverse transcription using at least one primer; amplifying the
cDNA so produced using a STEAP polynucleotides as sense and
antisense primers to amplify STEAP cDNAs therein; and detecting the
presence of the amplified STEAP cDNA. In another embodiment, a
method of detecting a STEAP gene in a biological sample comprises
first isolating genomic DNA from the sample; amplifying the
isolated genomic DNA using STEAP polynucleotides as sense and
antisense primers to amplify the STEAP gene therein; and detecting
the presence of the amplified STEAP gene. Any number of appropriate
sense and antisense probe combinations may be designed from the
nucleotide sequences provided for STEAP-1 (FIG. 1A), STEAP-2 (FIG.
9), STEAP-3 (FIG. 10A), or STEAP-4 (FIG. 10B), as appropriate, and
used for this purpose.
[0094] The invention also provides assays for detecting the
presence of a STEAP protein in a tissue of other biological sample
such as serum, bone, prostate, and other tissues, urine, cell
preparations, and the like. Methods for detecting a STEAP protein
are also well known and include, for example, immunoprecipitation,
immunohistochemical analysis, Western Blot analysis, molecular
binding assays, ELISA, ELIFA and the like.
[0095] For example, in one embodiment, a method of detecting the
presence of a STEAP protein in a biological sample comprises first
contacting the sample with a STEAP antibody, a STEAP-reactive
fragment thereof, or a recombinant protein containing an antigen
binding region of a STEAP antibody; and then detecting the binding
of STEAP protein in the sample thereto.
[0096] Methods for identifying a cell which expresses STEAP are
also provided. In one embodiment, an assay for identifying a cell
which expresses a STEAP gene comprises detecting the presence of
STEAP mRNA in the cell. Methods for the detection of particular
mRNAs in cells are well known and include, for example,
hybridization assays using complementary DNA probes (such as in
situ hybridization using labeled STEAP riboprobes, Northern blot
and related techniques) and various nucleic acid amplification
assays (such as RT-PCR using complementary primers specific for
STEAP, and other amplification type detection methods, such as, for
example, branched DNA, SISBA, TMA and the like). Alternatively, an
assay for identifying a cell which expresses a STEAP gene comprises
detecting the presence of STEAP protein in the cell or secreted by
the cell. Various methods for the detection of proteins are well
known in the art and may be employed for the detection of STEAP
proteins and STEAP expressing cells.
[0097] STEAP expression analysis may also be useful as a tool for
identifying and evaluating agents which modulate STEAP gene
expression. For example, STEAP-1 expression is significantly
upregulated in colon, bladder, pancreatic, ovarian and other
cancers. Identification of a molecule or biological agent that
could inhibit STEAP-1 over-expression may be of therapeutic value
in the treatment of cancer. Such an agent may be identified by
using a screen that quantifies STEAP expression by RT-PCR, nucleic
acid hybridization or antibody binding.
Assays for Determining STEAP Expression Status
[0098] Determining the status of STEAP expression patterns in an
individual may be used to diagnose cancer and may provide
prognostic information useful in defining appropriate therapeutic
options. Similarly, the expression status of STEAP may provide
information useful for predicting susceptibility to particular
disease stages, progression, and/or tumor aggressiveness. The
invention provides methods and assays for determining STEAP
expression status and diagnosing cancers which express STEAP.
[0099] In one aspect, the invention provides assays useful in
determining the presence of cancer in an individual, comprising
detecting a significant increase in STEAP mRNA or protein
expression in a test cell or tissue sample relative to expression
levels in the corresponding normal cell or tissue. In one
embodiment, the presence of STEAP-1 mRNA is evaluated in tissue
samples of the colon, pancreas, bladder, ovary, cervix, testis or
breast. The presence of significant STEAP-1 expression in any of
these tissues may be useful to indicate the emergence, presence
and/or severity of these cancers, since the corresponding normal
tissues do not express STEAP-1 mRNA. In a related embodiment,
STEAP-1 expression status may be determined at the protein level
rather than at the nucleic acid level. For example, such a method
or assay would comprise determining the level of STEAP-1 protein
expressed by cells in a test tissue sample and comparing the level
so determined to the level of STEAP expressed in a corresponding
normal sample. In one embodiment, the presence of STEAP-1 protein
is evaluated, for example, using immunohistochemical methods. STEAP
antibodies or binding partners capable of detecting STEAP protein
expression may be used in a variety of assay formats well known in
the art for this purpose.
[0100] Peripheral blood may be conveniently assayed for the
presence of cancer cells, including prostate, colon, pancreatic,
bladder and ovarian cancers, using RT-PCR to detect STEAP-1
expression. The presence of RT-PCR amplifiable STEAP-1 mRNA
provides an indication of the presence of one of these types of
cancer. RT-PCR detection assays for tumor cells in peripheral blood
are currently being evaluated for use in the diagnosis and
management of a number of human solid tumors. In the prostate
cancer field, these include RT-PCR assays for the detection of
cells expressing PSA and PSM (Verkalk et al., 1997, Urol. Res. 25:
373-384; Ghossein et al., 1995, J. Clin. Oncol. 13: 1195-2000;
Heston et al., 1995, Clin. Chem. 41: 1687-1688). RT-PCR assays are
well known in the art.
[0101] In another approach, a recently described sensitive assay
for detecting and characterizing carcinoma cells in blood may be
used (Racila et al., 1998, Proc. Natl. Acad. Sci. USA 95:
4589-4594). This assay combines immunomagnetic enrichment with
multiparameter flow cytometric and immunohistochemical analyses,
and is highly sensitive for the detection of cancer cells in blood,
reportedly capable of detecting one epithelial cell in 1 ml of
peripheral blood.
[0102] A related aspect of the invention is directed to predicting
susceptibility to developing cancer in an individual. In one
embodiment, a method for predicting susceptibility to cancer
comprises detecting STEAP mRNA or STEAP protein in a tissue sample,
its presence indicating susceptibility to cancer, wherein the
degree of STEAP mRNA expression present is proportional to the
degree of susceptibility.
[0103] Yet another related aspect of the invention is directed to
methods for gauging tumor aggressiveness. In one embodiment, a
method for gauging aggressiveness of a tumor comprises determining
the level of STEAP mRNA or STEAP protein expressed by cells in a
sample of the tumor, comparing the level so determined to the level
of STEAP mRNA or STEAP protein expressed in a corresponding normal
tissue taken from the same individual or a normal tissue reference
sample, wherein the degree of STEAP mRNA or STEAP protein
expression in the tumor sample relative to the normal sample
indicates the degree of aggressiveness.
[0104] Methods for detecting and quantifying the expression of
STEAP mRNA or protein are described herein and use standard nucleic
acid and protein detection and quantification technologies well
known in the art. Standard methods for the detection and
quantification of STEAP mRNA include in situ hybridization using
labeled STEAP riboprobes, Northern blot and related techniques
using STEAP polynucleotide probes, RT-PCR analysis using primers
specific for STEAP, and other amplification type detection methods,
such as, for example, branched DNA, SISBA, TMA and the like. In a
specific embodiment, semi-quantitative RT-PCR may be used to detect
and quantify STEAP mRNA expression as described in the Examples
which follow. Any number of primers capable of amplifying STEAP may
be used for this purpose, including but not limited to the various
primer sets specifically described herein. Standard methods for the
detection and quantification of protein may be used for this
purpose. In a specific embodiment, polyclonal or monoclonal
antibodies specifically reactive with the wild-type STEAP protein
may be used in an immunohistochemical assay of biopsied tissue.
Diagnostic Imaging of Human Cancers
[0105] Antibodies specific for STEAPs may be particularly useful in
radionuclide and other forms of diagnostic imaging of certain
cancers, given their expression profiles and cell surface location.
For example, immunohistochemical analysis of STEAP-1 protein
suggests that in normal tissues STEAP-1 is predominantly restricted
to prostate and bladder. The transmembrane orientation of STEAP-1
(and presumably STEAP-2, STEAP-3, STEAP-4) provides a target
readily identifiable by antibodies specifically reactive with
extracellular epitopes. This tissue restricted expression, and the
localization of STEAP to the cell surface of multiple cancers makes
STEAP an ideal candidate for diagnostic imaging. Accordingly, in
vivo imaging techniques may be used to image human cancers
expressing a STEAP protein.
[0106] For example, cell surface STEAP-1 protein is expressed at
very high levels in several human cancers, particularly prostate,
bladder, colon and ovarian cancers, and Ewing sarcoma. Moreover, in
normal tissues, STEAP-1 protein expression is largely restricted to
prostate. Thus, radiolabeled antibodies specifically reactive with
extracellular epitopes of STEAP-1 may be particularly useful in in
vivo imaging of solid tumors of the foregoing cancers. Such labeled
anti-STEAP-1 antibodies may provide very high level sensitivities
for the detection of metastasis of these cancers.
[0107] Preferably, monoclonal antibodies are used in the diagnostic
imaging methods of the invention.
Cancer Immunotherapy and Cancer Vaccines
[0108] The invention provides various immunotherapeutic methods for
treating prostate cancer, including antibody therapy, in vivo
vaccines, and ex vivo immunotherapy methods, which utilize
polynucleotides and polypeptides corresponding to STEAP and STEAP
antibodies. These therapeutic applications are described further in
the following subsections.
[0109] Applicants have accumulated strong and compelling evidence
that STEAP-1 is strongly expressed uniformly over the surface of
glandular epithelial cells within prostate and prostate cancer
cells. See, for details, immunohistochemical and Western blot
analyses of STEAP-1 protein expression presented in Examples 3C and
3D as well as the STEAP-1 mRNA expression profiles obtained from
the Northern blot and RT-PCR generated data presented in Examples 1
and 3A, B. In particular, immunohistochemical analysis results show
that the surface of human prostate epithelial cells (normal and
cancer) appear to be uniformly coated with STEAP-1. Biochemical
analysis confirms the cell surface localization of STEAP-1
initially suggested by its putative 6-transmembrane primary
structural elements and by the pericellular staining plainly
visualized by immunohistochemical staining.
[0110] STEAP-1 is uniformly expressed at high levels over the
surface of prostate glandular epithelia, an ideal situation for
immunotherapeutic intervention strategies which target
extracellular STEAP epitopes. Systemic administration of
STEAP-immunoreactive compositions would be expected to result in
extensive contact of the composition with prostate epithelial cells
via binding to STEAP-1 extracellular epitopes. Moreover, given the
near absence of STEAP-1 protein expression in normal human tissues,
there is ample reason to expect exquisite sensitivity without
toxic, non-specific and/or non-target effects caused by the binding
of the immunotherapeutic composition to STEAP-1 on non-target
organs and tissues.
[0111] In addition to the high level expression of STEAP-1 in
prostate and prostate cancer cells, STEAP-1 appears to be
substantially over-expressed in a variety of other human cancers,
including bladder, colon, pancreatic and ovarian cancers. In
particular, high level STEAP-1 mRNA expression is detected in all
tested prostate cancer tissues and cell lines, and in most of the
pancreatic, colon, and bladder cancer cell lines tested. High level
expression of STEAP-1 is also observed in some ovarian cancer cell
lines. Lower level expression is observed in some breast,
testicular, and cervical cancer cell lines. Very high level
expression is also detected in a Ewing sarcoma cell line.
Applicants have shown that cell surface STEAP-1 protein is
expressed in bladder and colon cancers, while there is no
detectable cell surface (or intracellular) STEAP-1 protein in
normal colon and low expression in normal bladder. Antibodies
specifically reactive with extracellular domains of STEAP-1 may be
useful to treat these cancers systemically, either as toxin or
therapeutic agent conjugates or as naked antibodies capable of
inhibiting cell proliferation or function.
[0112] STEAP-2 protein is also expressed in prostate cancer, and
may be expressed in other cancers as well. STEAP-2 mRNA analysis by
RT-PCR and Northern blot show that expression is restricted to
prostate in normal tissues, is also expressed in some prostate,
pancreatic, colon, testicular, ovarian and other cancers.
Therefore, antibodies reactive with STEAP-2 may be useful in the
treatment of prostate and other cancers. Similarly, although not
yet characterized by applicants, the expression of STEAP-3 and
STEAP-4 (as well as other STEAPs) may be associated with some
cancers. Thus antibodies reactive with these STEAP family member
proteins may also be useful therapeutically.
[0113] STEAP antibodies may be introduced into a patient such that
the antibody binds to STEAP on the cancer cells and mediates the
destruction of the cells and the tumor and/or inhibits the growth
of the cells or the tumor. Mechanisms by which such antibodies
exert a therapeutic effect may include complement-mediated
cytolysis, antibody-dependent cellular cytotoxicity, modulating the
physiologic function of STEAP, inhibiting ligand binding or signal
transduction pathways, modulating tumor cell differentiation,
altering tumor angiogenesis factor profiles, and/or by inducing
apoptosis. STEAP antibodies conjugated to toxic or therapeutic
agents may also be used therapeutically to deliver the toxic or
therapeutic agent directly to STEAP-bearing tumor cells.
[0114] Cancer immunotherapy using anti-STEAP antibodies may follow
the teachings generated from various approaches which have been
successfully employed with respect to other types of cancer,
including but not limited to colon cancer (Arlen et al., 1998, Crit
Rev Immunol 18:133-138), multiple myeloma (Ozaki et al., 1997,
Blood 90: 3179-3186; Tsunenari et al., 1997, Blood 90: 2437-2444),
gastric cancer (Kasprzyk et al., 1992, Cancer Res 52: 2771-2776),
B-cell lymphoma (Funakoshi et al., 1996, J Immunther Emphasis Tumor
Immunol 19: 93-101), leukemia (Zhong et al., 1996, Leuk Res 20:
581-589), colorectal cancer (Moun et al., 1994, Cancer Res 54:
6160-6166); Velders et al., 1995, Cancer Res 55: 4398-4403), and
breast cancer (Shepard et al., 1991, J Clin Immunol 11:
117-127).
[0115] Although STEAP antibody therapy may be useful for all stages
of the foregoing cancers, antibody therapy may be particularly
appropriate and in advanced or metastatic cancers. Combining the
antibody therapy method of the invention with a chemotherapeutic or
radiation regimen may be preferred in patients who have not
received chemotherapeutic treatment, whereas treatment with the
antibody therapy of the invention may be indicated for patients who
have received one or more chemotherapy. Additionally, antibody
therapy may also enable the use of reduced dosages of concomitant
chemotherapy, particularly in patients that do not tolerate the
toxicity of the chemotherapeutic agent very well.
[0116] It may be desirable for non-prostate cancer patients to be
evaluated for the presence and level of STEAP over-expression,
preferably using immunohistochemical assessments of tumor tissue,
quantitative STEAP imaging, or other techniques capable of reliably
indicating the presence and degree of STEAP overexpression.
Immunohistochemical analysis of tumor biopsies or surgical
specimens may be preferred for this purpose. Methods for
immunohistochemical analysis of tumor tissues are well known in the
art.
[0117] Anti-STEAP monoclonal antibodies useful in treating prostate
and other cancers include those which are capable of initiating a
potent immune response against the tumor and those which are
capable of direct cytotoxicity. In this regard, anti-STEAP mAbs may
elicit tumor cell lysis by either complement-mediated or
antibody-dependent cell cytotoxicity (ADCC) mechanisms, both of
which require an intact Fc portion of the immunoglobulin molecule
for interaction with effector cell Fc receptor sites or complement
proteins. In addition, anti-STEAP mAbs which exert a direct
biological effect on tumor growth are useful in the practice of the
invention. Potential mechanisms by which such directly cytotoxic
mAbs may act include inhibition of cell growth, modulation of
cellular differentiation, modulation of tumor angiogenesis factor
profiles, and the induction of apoptosis. The mechanism by which a
particular anti-STEAP mAb exerts an anti-tumor effect may be
evaluated using any number of in vitro assays designed to determine
ADCC, ADMMC, complement-mediated cell lysis, and so forth, as is
generally known in the art.
[0118] The anti-tumor activity of a particular anti-STEAP mAb, or
combination of anti-STEAP mAbs, may be evaluated in vivo using a
suitable animal model. For example, xenogenic prostate cancer
models wherein human prostate cancer explants or passaged xenograft
tissues are introduced into immune compromised animals, such as
nude or SCID mice, are appropriate in relation to prostate cancer
and have been described (Klein et al., 1997, Nature Medicine 3:
402-408). For Example, PCT Patent Application WO98/16628, Sawyers
et al., published Apr. 23, 1998, describes various xenograft models
of human prostate cancer capable of recapitulating the development
of primary tumors, micrometastasis, and the formation of
osteoblastic metastases characteristic of late stage disease.
Efficacy may be predicted using assays which measure inhibition of
tumor formation, tumor regression or metastasis, and the like.
[0119] It should be noted that the use of murine or other non-human
monoclonal antibodies, human/mouse chimeric mAbs may induce
moderate to strong immune responses in some patients. In the most
severe cases, such an immune response may lead to the extensive
formation of immune complexes which, potentially, can cause renal
failure. Accordingly, preferred monoclonal antibodies used in the
practice of the therapeutic methods of the invention are those
which are either fully human or humanized and which bind
specifically to the target antigen with high affinity but exhibit
low or no antigenicity in the patient.
[0120] The methods of the invention contemplate the administration
of single anti-STEAP mAbs as well as combinations, or "cocktails",
of different mAbs. Such mAb cocktails may have certain advantages
inasmuch as they contain mAbs which exploit different effector
mechanisms or combine directly cytotoxic mAbs with mAbs that rely
on immune effector functionality. Such mAbs in combination may
exhibit synergistic therapeutic effects. In addition, the
administration of anti-STEAP mAbs may be combined with other
therapeutic agents, including but not limited to various
chemotherapeutic agents, androgen-blockers, and immune modulators
(e.g., IL-2, GM-CSF). The anti-STEAP mAbs may be administered in
their "naked" or unconjugated form, or may have therapeutic agents
conjugated to them.
[0121] The anti-STEAP monoclonal antibodies used in the practice of
the method of the invention may be formulated into pharmaceutical
compositions comprising a carrier suitable for the desired delivery
method. Suitable carriers include any material which when combined
with the anti-STEAP mAbs retains the anti-tumor function of the
antibody and is non-reactive with the subject's immune systems.
Examples include, but are not limited to, any of a number of
standard pharmaceutical carriers such as sterile phosphate buffered
saline solutions, bacteriostatic water, and the like.
[0122] The anti-STEAP antibody formulations may be administered via
any route capable of delivering the antibodies to the tumor site.
Potentially effective routes of administration include, but are not
limited to, intravenous, intraperitoneal, intramuscular,
intratumor, intradermal, and the like. The preferred route of
administration is by intravenous injection. A preferred formulation
for intravenous injection comprises the anti-STEAP mAbs in a
solution of preserved bacteriostatic water, sterile unpreserved
water, and/or diluted in polyvinylchloride or polyethylene bags
containing 0.9% sterile Sodium Chloride for injection, USP. The
anti-STEAP mAb preparation may be lyophilized and stored as a
sterile powder, preferably under vacuum, and then reconstituted in
bacteriostatic water containing, for example, benzyl alcohol
preservative, or in sterile water prior to injection.
[0123] Treatment will generally involve the repeated administration
of the anti-STEAP antibody preparation via an acceptable route of
administration such as intravenous injection (IV), typically at a
dose in the range of about 0.1 to about 10 mg/kg body weight. Doses
in the range of 10-500 mg mAb per week may be effective and well
tolerated. Based on clinical experience with the Herceptin mAb in
the treatment of metastatic breast cancer, an initial loading dose
of approximately 4 mg/kg patient body weight IV followed by weekly
doses of about 2 mg/kg IV of the anti-STEAP mAb preparation may
represent an acceptable dosing regimen. Preferably, the initial
loading dose is administered as a 90 minute or longer infusion. The
periodic maintenance dose may be administered as a 30 minute or
longer infusion, provided the initial dose was well tolerated.
However, as one of skill in the art will understand, various
factors will influence the ideal dose regimen in a particular case.
Such factors may include, for example, the binding affinity and
half life of the mAb or mAbs used, the degree of STEAP
overexpression in the patient, the extent of circulating shed STEAP
antigen, the desired steady-state antibody concentration level,
frequency of treatment, and the influence of chemotherapeutic
agents used in combination with the treatment method of the
invention.
[0124] Optimally, patients should be evaluated for the level of
circulating shed STEAP antigen in serum in order to assist in the
determination of the most effective dosing regimen and related
factors. Such evaluations may also be used for monitoring purposes
throughout therapy, and may be useful to gauge therapeutic success
in combination with evaluating other parameters (such as serum PSA
levels in prostate cancer therapy).
Cancer Vaccines
[0125] The invention further provides prostate cancer vaccines
comprising a STEAP protein or fragment thereof. The use of a tumor
antigen in a vaccine for generating humoral and cell-mediated
immunity for use in anti-cancer therapy is well known in the art
and has been employed in prostate cancer using human PSMA and
rodent PAP immunogens (Hodge et al., 1995, Int. J. Cancer 63:
231-237; Fong et al., 1997, J. Immunol. 159: 3113-3117). Such
methods can be readily practiced by employing a STEAP protein, or
fragment thereof, or a STEAP-encoding nucleic acid molecule and
recombinant vectors capable of expressing and appropriately
presenting the STEAP immunogen.
[0126] For example, viral gene delivery systems may be used to
deliver a STEAP-encoding nucleic acid molecule. Various viral gene
delivery systems which can be used in the practice of this aspect
of the invention include, but are not limited to, vaccinia,
fowlpox, canarypox, adenovirus, influenza, poliovirus,
adeno-associated virus, lentivirus, and sindbus virus (Restifo,
1996, Curr. Opin. Immunol. 8: 658-663). Non-viral delivery systems
may also be employed by using naked DNA encoding a STEAP protein or
fragment thereof introduced into the patient (e.g.,
intramuscularly) to induce an anti-tumor response. In one
embodiment, the full-length human STEAP cDNA may be employed. In
another embodiment, STEAP nucleic acid molecules encoding specific
cytotoxic T lymphocyte (CTL) epitopes may be employed. CTL epitopes
can be determined using specific algorithms (e.g., Epimer, Brown
University) to identify peptides within a STEAP protein which are
capable of optimally binding to specified HLA alleles.
[0127] Various ex vivo strategies may also be employed. One
approach involves the use of dendritic cells to present STEAP
antigen to a patient's immune system. Dendritic cells express MHC
class I and II, B7 costimulator, and IL-12, and are thus highly
specialized antigen presenting cells. In prostate cancer,
autologous dendritic cells pulsed with peptides of the
prostate-specific membrane antigen (PSMA) are being used in a Phase
I clinical trial to stimulate prostate cancer patients' immune
systems (Tjoa et al., 1996, Prostate 28: 65-69; Murphy et al.,
1996, Prostate 29: 371-380). Dendritic cells can be used to present
STEAP peptides to T cells in the context of MHC class I and II
molecules. In one embodiment, autologous dendritic cells are pulsed
with STEAP peptides capable of binding to MHC molecules. In another
embodiment, dendritic cells are pulsed with the complete STEAP
protein. Yet another embodiment involves engineering the
overexpression of the STEAP gene in dendritic cells using various
implementing vectors known in the art, such as adenovirus (Arthur
et al., 1997, Cancer Gene Ther. 4: 17-25), retrovirus (Henderson et
al., 1996, Cancer Res. 56: 3763-3770), lentivirus, adeno-associated
virus, DNA transfection (Ribas et al., 1997, Cancer Res. 57:
2865-2869), and tumor-derived RNA transfection (Ashley et al.,
1997, J. Exp. Med. 186: 1177-1182).
[0128] Anti-idiotypic anti-STEAP antibodies can also be used in
anti-cancer therapy as a vaccine for inducing an immune response to
cells expressing a STEAP protein. Specifically, the generation of
anti-idiotypic antibodies is well known in the art and can readily
be adapted to generate anti-idiotypic anti-STEAP antibodies that
mimic an epitope on a STEAP protein (see, for example, Wagner et
al., 1997, Hybridoma 16: 33-40; Foon et al., 1995, J Clin Invest
96: 334-342; Herlyn et al., 1996, Cancer Immunol Immunother 43:
65-76). Such an anti-idiotypic antibody can be used in
anti-idiotypic therapy as presently practiced with other
anti-idiotypic antibodies directed against tumor antigens.
[0129] Genetic immunization methods may be employed to generate
prophylactic or therapeutic humoral and cellular immune responses
directed against cancer cells expressing STEAP. Constructs
comprising DNA encoding a STEAP protein/immunogen and appropriate
regulatory sequences may be injected, directly into muscle or skin
of an individual, such that the cells of the muscle or skin take-up
the construct and express the encoded STEAP protein/immunogen.
Expression of the STEAP protein immunogen results in the generation
of prophylactic or therapeutic humoral and cellular immunity
against prostate cancer. Various prophylactic and therapeutic
genetic immunization techniques known in the art may be used.
Kits
[0130] For use in the diagnostic and therapeutic applications
described or suggested above, kits are also provided by the
invention. Such kits may comprise a carrier means being
compartmentalized to receive in close confinement one or more
container means such as vials, tubes, and the like, each of the
container means comprising one of the separate elements to be used
in the method. For example, one of the container means may comprise
a probe which is or can be detectably labeled. Such probe may be an
antibody or polynucleotide specific for a STEAP protein or a STEAP
gene or message, respectively. Where the kit utilizes nucleic acid
hybridization to detect the target nucleic acid, the kit may also
have containers containing nucleotide(s) for amplification of the
target nucleic acid sequence and/or a container comprising a
reporter-means, such as a biotin-binding protein, such as avidin or
streptavidin, bound to a reporter molecule, such as an enzymatic,
florescent, or radionucleotide label.
EXAMPLES
[0131] Various aspects of the invention are further described and
illustrated by way of the several examples which follow, none of
which are intended to limit the scope of the invention.
Example 1
Isolation of cDNA Fragment of STEAP-1 Gene
Materials and Methods
Cell Lines and Human Tissues
[0132] All human cancer cell lines used in this study were obtained
from the ATCC. All cell lines were maintained in DMEM with 10%
fetal calf serum. PrEC (primary prostate epithelial cells) were
obtained from Clonetics and were grown in PrEBM media supplemented
with growth factors (Clonetics).
[0133] All human prostate cancer xenografts were originally
provided by Charles Sawyers (UCLA) (Klein et al., 1997). LAPC-4 AD
and LAPC-9 AD xenografts were routinely passaged as small tissue
chunks in recipient SCID males. LAPC-4 AI and LAPC-9 AI xenografts
were derived as described previously (Klein et al., 1997) and were
passaged in castrated males or in female SCID mice. A benign
prostatic hyperplasia tissue sample was patient-derived.
[0134] Human tissues for RNA and protein analyses were obtained
from the Human Tissue Resource Center (HTRC) at the UCLA (Los
Angeles, Calif.) and from QualTek, Inc. (Santa Barbara,
Calif.).
RNA Isolation:
[0135] Tumor tissue and cell lines were homogenized in Trizol
reagent (Life Technologies, Gibco BRL) using 10 ml/g tissue or 10
ml/10.sup.8 cells to isolate total RNA. Poly A RNA was purified
from total RNA using Qiagen's Oligotex mRNA Mini and Midi kits.
Total and mRNA were quantified by spectrophotometric analysis (O.D.
260/280 nm) and analyzed by gel electrophoresis.
Oligonucleotides:
[0136] The following HPLC purified oligonucleotides were used.
TABLE-US-00005 RSACDN (cDNA synthesis primer): (SEQ ID NO. 22)
5'TTTTGTACAAGCTT303' Adaptor 1: (SEQ ID NO: 23)
5'CTAATACGACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAGGT3' Adaptor 2: (SEQ ID
NO: 24) 3'GGCCCGTCCA5' (SEQ ID NO. 25)
5'GTAATACGACTCACTATAGGGCAGCGTGGTCGCGGCCGAGGT3' PCR primer 1: (SEQ
ID NO: 26) 3'CGGCTCCA5' (SEQ ID NO. 27) 5'CTAATACGACTCACTATAGGGC3'
Nested primer (NP)1: (SEQ ID NO. 28) 5'TCGAGCGGCCGCCCGGGCAGGT3'
Nested primer (NP)2: (SEQ ID NO. 29) 5'AGCGTGGTCGCGGCCGAGGT3'
Suppression Subtractive Hybridization:
[0137] Suppression Subtractive Hybridization (SSH) was used to
identify cDNAs corresponding to genes which may be up-regulated in
androgen dependent prostate cancer compared to benign prostatic
hyperplasia.
[0138] Double stranded cDNAs corresponding to the LAPC-4 AD
xenograft (tester) and the BPH tissue (driver) were synthesized
from 2 .mu.g of poly(A).sup.+ RNA isolated from xenograft and BPH
tissue, as described above, using CLONETECH'S PCR-Select cDNA
Subtraction Kit and 1 ng of oligonucleotide RSACDN as primer.
First- and second-strand synthesis were carried out as described in
the Kit's user manual protocol (CLONTECH Protocol No. PT1117-1,
Catalog No. K1804-1). The resulting cDNA was digested with Rsa I
for 3 hrs. at 37.degree. C. Digested cDNA was extracted with
phenol/chloroform (1:1) and ethanol precipitated.
[0139] Driver cDNA (BPH) was generated by combining in a 4 to 1
ratio Rsa I digested BPH cDNA with digested cDNA from mouse liver,
in order to ensure that murine genes were subtracted from the
tester cDNA (LAPC-4 AD).
[0140] Tester cDNA (LAPC-4 AD) was generated by diluting 1 .mu.l of
Rsa I digested LAPC-4 AD cDNA (400 ng) in 5 .mu.l of water. The
diluted cDNA (2 .mu.l, 160 ng) was then ligated to 2 .mu.l of
adaptor 1 and adaptor 2 (10 .mu.M), in separate ligation reactions,
in a total volume of 10 .mu.l at 16.degree. C. overnight, using 400
u of T4 DNA ligase (CLONTECH). Ligation was terminated with 1 .mu.l
of 0.2 M EDTA and heating at 72.degree. C. for 5 min.
[0141] The first hybridization was performed by adding 1.5 .mu.l
(600 ng) of driver cDNA to each of two tubes containing 1.5 .mu.l
(20 ng) adaptor 1- and adaptor 2-ligated tester cDNA. In a final
volume of 4 .mu.l, the samples were overlayed with mineral oil,
denatured in an MJ Research thermal cycler at 98.degree. C. for 1.5
minutes, and then were allowed to hybridize for 8 hrs at 68.degree.
C. The two hybridizations were then mixed together with an
additional 1 .mu.l of fresh denatured driver cDNA and were allowed
to hybridize overnight at 68.degree. C. The second hybridization
was then diluted in 200 .mu.l of 20 mM Hepes, pH 8.3, 50 mM NaCl,
0.2 mM EDTA, heated at 70.degree. C. for 7 min. and stored at
-20.degree. C.
PCR Amplification, Cloning and Sequencing of Gene Fragments
Generated from SSH:
[0142] To amplify gene fragments resulting from SSH reactions, two
PCR amplifications were performed. In the primary PCR reaction 1
.mu.l of the diluted final hybridization mix was added to 1 .mu.l
of PCR primer 1 (10 .mu.M), 0.5 .mu.l dNTP mix (10 .mu.M), 2.5
.mu.l 10.times. reaction buffer (CLONTECH) and 0.5 .mu.l 50.times.
Advantage cDNA polymerase Mix (CLONTECH) in a final volume of 25
.mu.l. PCR 1 was conducted using the following conditions:
75.degree. C. for 5 min., 94.degree. C. for 25 sec., then 27 cycles
of 94.degree. C. for 10 sec, 66.degree. C. for 30 sec, 72.degree.
C. for 1.5 min. Five separate primary PCR reactions were performed
for each experiment. The products were pooled and diluted 1:10 with
water. For the secondary PCR reaction, 1 .mu.l from the pooled and
diluted primary PCR reaction was added to the same reaction mix as
used for PCR 1, except that primers NP1 and NP2 (10 .mu.M) were
used instead of PCR primer 1. PCR 2 was performed using 10-12
cycles of 94.degree. C. for 10 sec, 68.degree. C. for 30 sec,
72.degree. C. for 1.5 minutes. The PCR products were analyzed using
2% agarose gel electrophoresis.
[0143] The PCR products were inserted into pCR2.1 using the T/A
vector cloning kit (Invitrogen). Transformed E. coli were subjected
to blue/white and ampicillin selection. White colonies were picked
and arrayed into 96 well plates and were grown in liquid culture
overnight. To identify inserts, PCR amplification was performed on
1 ml of bacterial culture using the conditions of PCR1 and NP1 and
NP2 as primers. PCR products were analyzed using 2% agarose gel
electrophoresis.
[0144] Bacterial clones were stored in 20% glycerol in a 96 well
format. Plasmid DNA was prepared, sequenced, and subjected to
nucleic acid homology searches of the GenBank, dBest, and NCI-CGAP
databases.
RT-PCR Expression Analysis:
[0145] First strand cDNAs were generated from 1 .mu.g of mRNA with
oligo (dT)12-18 priming using the Gibco-BRL Superscript
Preamplification system. The manufacturers protocol was used and
included an Incubation for 50 min at 42.degree. C. with reverse
transcriptase followed by RNAse H treatment at 37.degree. C. for 20
min. After completing the reaction, the volume was increased to 200
.mu.l with water prior to normalization. First strand cDNAs from 16
different normal human tissues were obtained from Clontech.
[0146] Normalization of the first strand cDNAs from multiple
tissues was performed by using the primers 5'
atatcgccgcgctcgtcgtcgacaa3' (SEQ ID NO: 33) and 5'
agccacacgcagctcattgtagaagg3' (SEQ ID NO: 34) to amplify
.beta.-actin. First strand cDNA (5 .mu.l) was amplified in a total
volume of 50 .mu.l containing 0.4 .mu.M primers, 0.2 .mu.M each
dNTPs, 1.times.PCR buffer (Clontech, 10 mM Tris-HCL, 1.5 mM
MgCl.sub.2, 50 mM KCl, pH8.3) and 1.times. Klentaq DNA polymerase
(Clontech). Five .mu.l of the PCR reaction was removed at 18, 20,
and 22 cycles and used for agarose gel electrophoresis. PCR was
performed using an MJ Research thermal cycler under the following
conditions: initial denaturation was at 94.degree. C. for 15 sec,
followed by a 18, 20, and 22 cycles of 94.degree. C. for 15 sec,
65.degree. C. for 2 min, 72.degree. C. for 5 sec. A final extension
at 72.degree. C. was carried out for 2 min. After agarose gel
electrophoresis, the band intensities of the 283 bp .beta.-actin
bands from multiple tissues were compared by visual inspection.
Dilution factors for the first strand cDNAs were calculated to
result in equal .beta.-actin band intensities in all tissues after
22 cycles of PCR. Three rounds of normalization were required to
achieve equal band intensities in all tissues after 22 cycles of
PCR.
[0147] To determine expression levels of the 8P1 D4 gene, 5 .mu.l
of normalized first strand cDNA was analyzed by PCR using 25, 30,
and 35 cycles of amplification using the following primer
pairs:
TABLE-US-00006 (SEQ ID NO. 14) 5' ACT TTG TTG ATG ACC AGG ATT GGA
3' (SEQ ID NO. 15) 5' CAG AAC TTC AGC ACA CAC AGG AAC 3'
[0148] Semi quantitative expression analysis was achieved by
comparing the PCR products at cycle numbers that give light band
intensities.
Results:
[0149] Several SSH experiments were conduced as described in the
Materials and Methods, supra, and led to the isolation of numerous
candidate gene fragment clones. All candidate clones were sequenced
and subjected to homology analysis against all sequences in the
major public gene and EST databases in order to provide information
on the identity of the corresponding gene and to help guide the
decision to analyze a particular gene for differential expression.
In general, gene fragments which had no homology to any known
sequence in any of the searched databases, and thus considered to
represent novel genes, as well as gene fragments showing homology
to previously sequenced expressed sequence tags (ESTs), were
subjected to differential expression analysis by RT-PCR and/or
Northern analysis.
[0150] One of the cDNA clones, designated 8P1D4, was 436 by in
length and showed homology to an EST sequence in the NCI-CGAP tumor
gene database. The full length cDNA encoding the 8P1D4 gene was
subsequently isolated using this cDNA and re-named STEAP-1 (Example
2, below). The 8P1D4 cDNA nucleotide sequence corresponds to
nucleotide residues 150 through 585 in the STEAP-1 cDNA sequence as
shown in FIG. 1A. Another clone, designated 28P3E1, 561 bp in
length showed homology to a number of EST sequences in the NCI-CGAP
tumor gene database or in other databases. Part of the 28P3E1
sequence (356 bp) is identical to an EST derived from human fetal
tissue. After the full length STEAP-1 cDNA was obtained and
sequenced, it became apparent that this clone also corresponds to
STEAP-1 (more specifically, to residues 622 through the 3' end of
the STEAP-1 nucleotide sequence as shown in FIG. 1A).
[0151] Differential expression analysis by RT-PCR using primers
derived from the 8P1D4 cDNA clone showed that the 8P1D4 (STEAP-1)
gene is expressed at approximately equal levels in normal prostate
and the LAPC-4 and LAPC-9 xenografts (FIG. 2, panel A). Further
RT-PCR expression analysis of first strand cDNAs from 16 normal
tissues showed greatest levels of 8P1D4 expression in prostate.
Substantially lower level expression in several other normal
tissues (i.e., colon, ovary, small intestine, spleen and testis)
was detectable only at 30 cycles of amplification (FIG. 2, panels B
and C).
Example 2
Isolation of Full Length STEAP-1 Encoding cDNA
[0152] The 436 bp 8P1D4 gene fragment (Example 1) was used to
isolate additional cDNAs encoding the 8P1D4/STEAP-1 gene. Briefly,
a normal human prostate cDNA library (Clontech) was screened with a
labeled probe generated from the 436 bp 8P1D4 cDNA. One of the
positive clones, clone 10, is 1195 bp in length and encodes a 339
amino acid protein having nucleotide and encoded amino acid
sequences bearing no significant homology to any known human genes
or proteins (homology to a rat Kidney Injury Protein recently
described in International Application WO98/53071). The encoded
protein contains at least 6 predicted transmembrane motifs implying
a cell surface orientation (see FIG. 1A, predicted transmembrane
motifs underlined). These structural features led to the
designation "STEAP", for "Six Transmembrane Epithelial Antigen of
the Prostate". Subsequent identification of additional STEAP
proteins led to the re-designation of the 8P1D4 gene product as
"STEAP-1." The STEAP-1 cDNA and encoded amino acid sequences are
shown in FIG. 1A and correspond to SEQ ID NOs: 1 and 2,
respectively. STEAP-1 cDNA clone 10 has been deposited with the
American Type Culture Collection ("ATCC") (Mannassas, Va.) as
plasmid 8P1D4 clone 10.1 on Aug. 26, 1998 as ATCC Accession Number
98849. The STEAP-1 cDNA clone can be excised therefrom using
EcoRI/XbaI double digest (EcoRI at the 5' end, XbaI at the 3'
end).
Example 3
STEAP-1 Gene and Protein Expression Analysis
[0153] In order to begin to characterize the biological
characteristics of STEAP-1, an extensive evaluation of STEAP-1 mRNA
and STEAP-1 protein expression across a variety of human tissue
specimens was undertaken. This evaluation included Northern blot,
Western blot and immunohistochemical analysis of STEAP-1 expression
in a large number of normal human tissues, human prostate cancer
xenografts and cell lines, and various other human cancer cell
lines.
Example 3A
Northern Blot Analysis of STEAP-1 mRNA Expression in Normal Human
Tissues
[0154] Initial analysis of STEAP-1 mRNA expression in normal human
tissues was conducted by Northern blotting two multiple tissue
blots obtained from Clontech (Palo Alto, Calif.), comprising a
total of 16 different normal human tissues, using labeled STEAP-1
clone 10 as a probe. RNA samples were quantitatively normalized
with a .beta.-actin probe. The results are shown in FIG. 3A. The
highest expression level was detected in normal prostate, with an
approximately 5-10 fold lower level of expression detected in colon
and liver. These northern blots showed two transcripts of
approximately 1.4 kb and 4.0 kb, the former of which corresponds to
the full length STEAP-1 clone 10 cDNA, which encodes the entire
STEAP-1 open reading frame. The larger transcript was separately
cloned as a 3627 bp cDNA from a normal prostate library, the
sequence of which contains a 2399 bp intron (FIG. 4).
[0155] This initial analysis was extended by using the STEAP-1
clone 10 probe to analyze an RNA dot blot matrix of 37 normal human
tissues (Clontech, Palo Alto, Calif.; Human Master Blot.TM.). The
results are shown in FIG. 3B and show strong STEAP-1 expression
only in prostate. Very low level STEAP-1 RNA expression was
detected in liver, lung, trachea and fetal liver tissue, at perhaps
a 5-fold lower level compared to prostate. No expression was
detected in any of the remaining tissues. Based on these analyses,
significant STEAP-1 expression appears to be prostate specific in
normal tissues.
Example 3B
Northern Blot Analysis of STEAP-1 mRNA Expression in Prostate
Cancer Xenografts and Cell Lines
[0156] To analyze STEAP-1 expression in human cancer tissues and
cell lines, RNAs derived from human prostate cancer xenografts and
an extensive panel of prostate and non-prostate cancer cell lines
were analyzed by Northern blot using STEAP-1 cDNA clone 10 as
probe. All RNA samples were quantitatively normalized by ethiduim
bromide staining and subsequent analysis with a labeled
.beta.-actin probe.
[0157] The results, presented in FIG. 5, show high level STEAP-1
expression in all the LAPC xenografts and all of the prostate
cancer cell lines. Expression in the LAPC-9 xenografts was higher
compared to the LAPC-4 xenografts, with no significant difference
observed between androgen-dependent and androgen-independent
sublines (FIG. 5A). Expression in the LAPC-4 xenografts was
comparable to expression in normal prostate. Lower levels of
expression were detected in PrEC cells (Clonetics), which represent
the basal cell compartment of the prostate. Analysis of prostate
cancer cell lines showed highest expression levels in LNCaP, an
androgen dependent prostate carcinoma cell line. Significant
expression was also detected in the androgen-independent cell lines
PC-3 and DU145. High levels of STEAP expression were also detected
in LAPC-4 and LAPC-9 tumors that were grown within the tibia of
mice as a model of prostate cancer bone metastasis (FIG. 5B).
[0158] Significantly, very strong STEAP-1 expression was also
detected in many of the non-prostate human cancer cell lines
analyzed (FIG. 5A). Particularly high level expression was observed
in RD-ES cells, an Ewing sarcoma (EWS) derived cell line.
Additionally, very high level expression was also detected in
several of the colon cancer cell lines (e.g., CaCo-2, LoVo, T84 and
Colo-205), bladder carcinoma cell lines (e.g., SCABER, UM-UC-3,
TCCSUP and 5637), ovarian cancer cell lines (e.g., OV-1063 and SW
626) and pancreatic cancer cell lines (e.g., HPAC, Capan-1, PANC-1
and BxPC-3). These results, combined with the absence of strong
expression in the corresponding normal tissues (FIG. 3), indicate
that STEAP-1 may be generally up-regulated in these types (as well
as other types) of human cancers.
Example 3C
Western Blot Analysis of STEAP-1 Protein Expression in Prostate and
Other Cancers
[0159] A 15 mer peptide corresponding to amino acid residues 14
through 28 of the STEAP-1 amino acid sequence as shown in FIG. 1A
(WKMKPRRNLEEDDYL) (SEQ ID NO: 35) was synthesized and used to
immunize sheep for the generation of sheep polyclonal antibodies
towards the amino-terminus of the protein (anti-STEAP-1) as
follows. The peptide was conjugated to KLH (keyhole limpet
hemocyanin) The sheep was initially immunized with 400 .mu.g of
peptide in complete Freund's adjuvant. The animal was subsequently
boosted every two weeks with 200 .mu.g of peptide in incomplete
Freund's adjuvant. Anti-STEAP antibody was affinity-purified from
sheep serum using STEAP peptide coupled to Affi-Gel 10 (Bio Rad).
Purified antibody is stored in phosphate-buffered saline with 0.1%
sodium azide.
[0160] To test antibody specificity, the cDNA of STEAP-1 was cloned
into a retroviral expression vector (pSR.alpha.tkneo, Muller et
al., 1991, MCB 11:1785). NIH 3T3 cells were infected with
retroviruses encoding STEAP-1 and were selected in G418 for 2
weeks. Western blot analysis of protein extracts of infected and
un-infected NIH 3T3 cells showed expression of a protein with an
apparent molecular weight of 36 kD only in the infected cells (FIG.
6, lanes marked "3T3 STEAP" AND "3T3").
[0161] The anti-STEAP-1 polyclonal antibody was used to probe
Western blots of cell lysates prepared from a variety of prostate
cancer xenograft tissues, prostate cancer cell lines and other
non-prostate cancer cell lines. Protein samples (20 .mu.g each)
were quantitatively normalized by probing the blots with an
anti-Grb-2 antibody.
[0162] The results are shown in FIG. 6. STEAP-1 protein was
detected in all of the LAPC prostate cancer xenografts, all of the
prostate cancer cell lines, a primary prostate cancer specimen and
its matched normal prostate control. Highest STEAP-1 protein
expression was detected in the LAPC-9 xenograft and in LNCaP cells,
in agreement with the Northern blot analysis described immediately
above. High level expression was also observed in the bladder
carcinoma cell line UM-UC-3. Expression in other cancer cell lines
was also detectable (FIG. 6).
Example 3D
Immunohistochemical Analysis of STEAP-1 Protein Expression in
Prostate Tumor Biopsy and Surgical Specimens
[0163] To determine the extent of STEAP-1 protein expression in
clinical materials, tissue sections were prepared from a variety of
prostate cancer biopsies and surgical samples for
immunohistochemical analysis. Tissues were fixed in 10% formalin,
embedded in paraffin, and sectioned according to standard protocol.
Formalin-fixed, paraffin-embedded sections of LNCaP cells were used
as a positive control. Sections were stained with an anti-STEAP-1
polyclonal antibody directed against a STEAP-1 N-terminal epitope
(as described immediately above). LNCaP sections were stained in
the presence of an excess amount of the STEAP-1 N-terminal peptide
immunogen used to generate the polyclonal antibody (peptide 1) or a
non-specific peptide derived from a distinct region of the STEAP-1
protein (peptide 2; YQQVQQNKEDAWIEH); (SEQ ID NO: 30)).
[0164] The results are shown in FIG. 8. LNCaP cells showed
uniformly strong peri-cellular staining in all cells (FIG. 8B).
Excess STEAP N-terminal peptide (peptide 1) was able to
competitively inhibit antibody staining (FIG. 8A), while peptide 2
had no effect (FIG. 8B). Similarly, uniformly strong peri-cellular
staining was seen in the LAPC-9 (FIG. 8F) and LAPC-4 prostate
cancer xenografts (data not shown). These results are clear and
suggest that the staining is STEAP specific. Moreover, these
results visually localize STEAP to the plasma membrane,
corroborating the biochemical findings presented in Example 4
below.
[0165] The results obtained with the various clinical specimens are
shown in FIG. 8C (normal prostate tissue), FIG. 8D (grade 3
prostatic carcinoma), and FIG. 8E (grade 4 prostatic carcinoma),
and are also included in the summarized results shown in TABLE 1.
Light to strong staining was observed in the glandular epithelia of
all prostate cancer samples tested as well as in all samples
derived from normal prostate or benign disease. The signal appears
to be strongest at the cell membrane of the epithelial cells,
especially at the cell-cell junctions (FIG. 8C, D and E) and is
also inhibited with excess STEAP N-terminal peptide 1 (data not
shown). Some basal cell staining is also seen in normal prostate
(FIG. 8c), which is more apparent when examining atrophic glands
(data not shown). STEAP-1 seems to be expressed at all stages of
prostate cancer since lower grades (FIG. 8D), higher grades (FIG.
8E) and metastatic prostate cancer (represented by LAPC-9; FIG. 8F)
all exhibit strong staining.
[0166] Immunohistochemical staining of a large panel of normal
non-prostate tissues showed no detectable STEAP-1 expression in 24
of 27 of these normal tissues (Table 1). Only three tissue samples
showed some degree of anti-STEAP-1 staining. In particular, normal
bladder exhibited low levels of cell surface staining in the
transitional epithelium (FIG. 8G). Pancreas and pituitary showed
low levels of cytoplasmic staining (Table 1). It is unclear whether
the observed cytoplasmic staining is specific or is due to
non-specific binding of the antibody, since Northern blotting
showed little to no STEAP-1 expression in pancreas (FIG. 3). Normal
colon, which exhibited higher mRNA levels than pancreas by Northern
blotting (FIG. 3), exhibited no detectable staining with anti-STEAP
antibodies (FIG. 8H). These results indicate that cell surface
expression of STEAP-1 in normal tissues appears to be restricted to
prostate and bladder.
TABLE-US-00007 TABLE 1 IMMUNOHISTOCHEMICAL STAINING OF HUMAN
TISSUES WITH ANTI-STEAP-1 POLYCLONAL ANTIBODY STAINING INTENSITY
TISSUE NONE cerebellum, cerebral cortex, spinal cord, heart,
skeletal muscle, artery, thymus, spleen, bone marrow, lymph node,
lung, colon, liver, stomach, kidney, testis, ovary, fallopian
tubes, placenta, uterus, breast, adrenal gland, thyroid gland,
skin, bladder (3/5) LIGHT TO bladder (2/5), pituitary gland
MODERATE (cytoplasmic), pancreas (cytoplasmic), BPH (3/5), prostate
cancer (3/10) STRONG prostate (2/2), BPH (2/5), prostate cancer**
(7/10) *In cases where more than one sample is analyzed per tissue,
the numbers in brackets indicates how many samples correspond to
the staining category/total analyzed. **Prostate cancer grades
ranged from Gleason grades 3 to 5.
Example 4
Biochemical Characterization of STEAP-1 Protein
[0167] To initially characterize the STEAP-1 protein, cDNA clone 10
(SEQ ID NO. 1) was cloned into the pcDNA 3.1 Myc-His plasmid
(Invitrogen), which encodes a 6H is tag at the carboxyl-terminus,
transfected into 293T cells, and analyzed by flow cytometry using
anti-His monoclonal antibody (His-probe, Santa Cruz) as well as the
anti-STEAP-1 polyclonal antibody described above. Staining of cells
was performed on intact cells as well as permeabilized cells. The
results indicated that only permeabilized cells stained with both
antibodies, suggesting that both termini of the STEAP-1 protein are
localized intracellularly. It is therefore possible that one or
more of the STEAP-1 protein termini are associated with
intracellular organelles rather than the plasma membrane.
[0168] To determine whether STEAP-1 protein is expressed at the
cell surface, intact STEAP-1-transfected 293T cells were labeled
with a biotinylation reagent that does not enter live cells.
STEAP-1 was then immunoprecipitated from cell extracts using the
anti-His and anti-STEAP antibodies. SV40 large T antigen, an
intracellular protein that is expressed at high levels in 293T
cells, and the endogenous cell surface transferrin receptor were
immunoprecipitated as negative and positive controls, respectively.
After immunoprecipitation, the proteins were transferred to a
membrane and visualized with horseradish peroxidase-conjugated
streptavidin. The results of this analysis are shown in FIG. 7.
Only the transferrin receptor (positive control) and STEAP-1 were
labeled with biotin, while the SV40 large T antigen (negative
control) was not detectably labeled (FIG. 7A). Since only cell
surface proteins are labeled with this technique, it is clear from
these results that STEAP-1 is a cell surface protein. Combined with
the results obtained from the flow cytometric analysis, it is clear
that STEAP-1 is a cell surface protein with intracellular amino-
and carboxyl-termini.
[0169] Furthermore, the above results together with the STEAP-1
secondary structural predictions, shows that STEAP-1 is a type IIIa
membrane protein with a molecular topology of six potential
transmembrane domains, 3 extracellular loops, 2 intracellular loops
and two intracellular termini. A schematic representation of
STEAP-1 protein topology relative to the cell membrane is shown in
FIG. 1B.
[0170] In addition, prostate, bladder and colon cancer cells were
directly analyzed for cell surface expression of STEAP-1 by
biotinylation studies. Briefly, biotinylated cell surface proteins
were affinity purified with streptavidin-gel and probed with the
anti-STEAP-1 polyclonal antibody described above. Western blotting
of the streptavidin purified proteins clearly show cell surface
biotinylation of endogenous STEAP-1 in all prostate (LNCaP, PC-3,
DU145), bladder (UM-UC-3, TCCSUP) and colon cancer (LoVo, Colo)
cells tested, as well as in NIH 3T3 cells infected with a STEAP-1
encoding retrovirus, but not in non-expressing NIH 3T3 cells used
as a negative control (FIG. 7B). In a further negative control,
STEAP-1 protein was not detected in streptavidin precipitates from
non-biotinylated STEAP expressing cells (FIG. 7B).
Example 5
Identification and Structural Analysis of STEAP-2 and Other Human
STEAP Family Members
[0171] STEAP-1 has no homology to any known human genes. In an
attempt to identify additional genes that are homologous to
STEAP-1, the protein sequence of STEAP-1 was used as an electronic
probe to identify family members in the public EST (expression
sequence tag) database (dbest). Using the "tblastn" function in
NCBI (National Center for Biotechnology Information), the dbest
database was queried with the STEAP-1 protein sequence. This
analysis revealed additional putative STEAP-1 homologues or STEAP
family members, as further described below.
[0172] In addition, SSH cloning experiments also identified a
STEAP-1 related cDNA fragment, clone 98P4B6. This clone was
isolated from SSH cloning using normal prostate cDNA as tester and
LAPC-4 AD cDNA as driver. A larger partial sequence of the 98P4B6
clone was subsequently isolated from a normal prostate library;
this clone encodes an ORF of 173 amino acids with close homology to
the primary structure of STEAP-1, and thus was designated STEAP-2.
A full length STEAP-2 cDNA of 2454 bp was isolated from a prostate
library. The STEAP-2 nucleotide and encoded ORF amino acid
sequences are shown in FIG. 9. An amino acid alignment of the
STEAP-1 and partial STEAP-2 primary structures is shown in FIGS.
11A and 11B. STEAP-1 and -2 share 61% identity over their 171 amino
acid residue overlap (FIG. 11B). The STEAP-2 cDNA has been
deposited with the American Type Culture Collection ("ATCC")
(Mannassas, Va.) as plasmid 98P4B6-GTD3 as ATCC Accession Number
PTA-311.
[0173] This deposit was made under the provisions of the Budapest
Treaty on International Recognition of the Deposit of
Microorganisms for the Purpose of Patent Procedure and the
Regulations there under (Budapest Treaty). This assures maintenance
of a viable culture of the deposit for 30 years from the date of
deposit and for at least five (5) years after the most recent
request for the furnishing of a sample of the deposit received by
the depository. The deposits will be made available by ATCC under
the terms of the Budapest Treaty, and subject to an agreement
between Genentech, Inc. and ATCC, which assures that all
restrictions imposed by the depositor on the availability to the
public of the deposited material will be irrevocably removed upon
the granting of the pertinent U.S. patent, assures permanent and
unrestricted availability of the progeny of the culture of the
deposit to the public upon issuance of the pertinent U.S. patent or
upon laying open to the public of any U.S. or foreign patent
application, whichever comes first, and assures availability of the
progeny to one determined by the U.S. Commissioner of Patents and
Trademarks to be entitled thereto according to 35 U.S.C. .sctn.122
and the Commissioner's rule pursuant thereto (including 37 C.F.R.
.sctn.1.14 with particular reference to 886 OG 638).
[0174] The assignee of the present application has agreed that if a
culture of the materials on deposit should die or be lost or
destroyed when cultivated under suitable conditions, the materials
will be promptly replaced on notification with another of the same.
Availability of the deposited material is not to be construed as a
license to practice the invention in contravention of the rights
granted under the authority of any government in accordance with
its patent laws.
[0175] The STEAP-2 cDNA (98P4B6-GTD3) contains a 355 bp 5'UTR
(untranslated region) that is 72% GC rich, suggesting that it
contains translational regulatory elements. The cDNA encodes an
open reading frame (ORF) of 454 amino acids (a.a.) with six
potential transmembrane domains. This is in contrast to STEAP,
which is 339 a.a. in length. Alignment with STEAP-1 demonstrates
54.9% identity over a 237 amino acid overlap. Interestingly, the
locations of the six putative transmembrane domains in STEAP-2
coincide with the locations of the transmembrane domains in STEAP-1
(see alignment). The homology of STEAP-2 with STEAP-1 is highest in
the regions spanned by the first putative extracellular loop to the
fifth transmembrane domain. This analysis and the sequence of
STEAP-2 suggest some significant differences between STEAP-1 and
STEAP-2: STEAP-2 exhibits a 205 a.a. long intracellular N-terminus
(compared to 69 a.a. in STEAP-1) and a short 4 a.a. intracellular
C-terminus (compared to 26 a.a. in STEAP-1). These differences
could imply significant differences in function and/or interaction
with intracellular signaling pathways. To identify a unique mouse
EST corresponding to STEAP-2, the unique N-terminus of STEAP-2 was
used to query the dbest database. One mouse EST was isolated
(AI747886, mouse kidney) that may be used in the identification of
mouse STEAP-2 and in expression analysis of STEAP-2 in mouse.
[0176] Two ESTs encoding ORFs bearing close homology to the STEAP-1
and STEAP-2 sequences were also identified by electronic probing
with the STEAP-1 protein sequence. These ESTs (AI139607 and R80991)
were provisionally designated STEAP-3 and STEAP-4. A full length
cDNA encoding STEAP-3 was subsequently cloned, and its nucleotide
and deduced amino acid sequences are shown in FIG. 10A. The
nucleotide sequences of the ESTs corresponding to the STEAPs are
reproduced in FIG. 10B.
[0177] An amino acid alignment of the structures of STEAP-1,
STEAP-2, STEAP-3 and the partial sequence of the putative STEAP-4
is shown in FIG. 11A. This alignment shows a close structural
similarity between all four STEAP family proteins, particularly in
the predicted transmembrane domains. As indicated above, STEAP-1
and STEAP-2 demonstrate 54.9% identity over a 237 amino acid
overlap. STEAP-1 and STEAP-3 are 40.9% identical over a 264 amino
acid region, while STEAP-2 and STEAP-3 are 47.8% identical over a
416 amino acid region.
Example 6
Expression Analysis of STEAP-2 and Other Human STEAP Family
Members
Example 6A
Tissue Specific Expression of STEAP Family Members in Normal Human
Tissues
[0178] RT-PCR analysis of STEAP-2 shows expression in all the LAPC
prostate cancer xenografts and in normal prostate (FIG. 14, panel
A). Analysis of 8 normal human tissues shows prostate-specific
expression after 25 cycles of amplification (FIG. 14, panel B).
Lower level expression in other tissues was detected only after 30
cycles of amplification. Northern blotting for STEAP-2 shows a
pattern of 2 transcripts (approximately 3 and 8 kb in size)
expressed only in prostate (and at significantly lower levels in
the LAPC xenografts), with no detectable expression in any of the
15 other normal human tissues analyzed (FIG. 15, panel C). Thus,
STEAP-2 expression in normal human tissues appears to be highly
prostate-specific.
[0179] Expression analysis of STEAP family members in normal
tissues was performed by Northern blot and/or RT-PCR. All STEAP
family members appeared to exhibit tissue restricted expression
patterns. STEAP-3/AI139607 expression is shown in FIG. 12A
(Northern) and FIG. 12B (RT-PCR). STEAP-4/R80991 expression is
shown in FIG. 13.
Example 6B
Expression of STEAP-2 in Various Cancer Cell Lines
[0180] The RT-PCR results above suggested that the different STEAP
family members exhibit different tissue expression patterns.
Interestingly, STEAP-2, which appears very prostate-specific, seems
to be expressed at lower levels in the LAPC xenografts. This is in
contrast to STEAP-1, which is highly expressed in both normal and
malignant prostate tissue.
[0181] To better characterize this suggested difference in the
STEAP-2 prostate cancer expression profile (relative to STEAP-1),
Northern blotting was performed on RNA derived from the LAPC
xenografts, as well as several prostate and other cancer cell
lines, using a STEAP-2 specific probe (labeled cDNA clone 98P4B6).
The results are shown in FIG. 16 and can be summarized as follows.
STEAP-2 is highly expressed in normal prostate and in some of the
prostate cancer xenografts and cell lines. More particularly, very
strong expression was observed in the LAPC-9 AD xenograft and the
LNCaP cells. Significantly attenuated or no expression was observed
in the other prostate cancer xenografts and cell lines. Very strong
expression was also evident in the Ewing Sarcoma cell line RD-ES.
Unlike STEAP-1, which is highly expressed in cancer cell lines
derived from bladder, colon, pancreatic and ovarian tumors, STEAP-2
showed low to non-detectable expression in these same cell lines
(compare with FIG. 5). Interestingly, STEAP-2 was also
non-detectable in PrEC cells, which are representative of the
normal basal cell compartment of the prostate. These results
suggests that expression of STEAP-1 and STEAP-2 are differentially
regulated. While STEAP-1 may be a gene that is generally
up-regulated in cancer, STEAP-2 may be a gene that is more
restricted to normal prostate and prostate cancer.
Example 7
Chromosomal Localization of STEAP Genes
[0182] The chromosomal localization of STEAP-1 was determined using
the GeneBridge 4 Human/Hamster radiation hybrid (RH) panel (Walter
et al., 1994, Nat. Genetics 7:22) (Research Genetics, Huntsville
Ala.), while STEAP-2 and the STEAP homologues were mapped using the
Stanford G3 radiation hybrid panel (Stewart et al., 1997, Genome
Res. 7:422).
[0183] The following PCR primers were used for STEAP-1:
TABLE-US-00008 8P1D4.1 5'ACTTTGTTGATGACCAGGATTGGA 3' (SEQ ID NO:
14) 8P1D4.2 5'CAGAACTTCAGCACACACAGGAAC 3' (SEQ ID NO: 15)
[0184] The resulting STEAP-1 mapping vector for the 93 radiation
hybrid panel DNAs
(2100000201101010001000000101110101221000111001110110101000100010001-0100-
1 021000001111001010000), and the mapping program available at the
internet address for the Whitehead Institute for Biomedical
researched, localized the STEAP-1 gene to chromosome 7p22.3,
telomeric to D7S531.
[0185] The following PCR primers were used for 98P4B6/STEAP-2:
TABLE-US-00009 98P4B6.1 5' GACTGAGCTGGAACTGGAATTTGT 3' (SEQ ID NO:
20) 98P4B6.2 5' TTTGAGGAGACTTCATCTCACTGG 3' (SEQ ID NO: 21)
[0186] The resulting vector
(000001001000000000000000000000001001000000000010001000
00000000001000010101010010011), and the mapping program available
at the internet address for the Stanford Human Genome Center, maps
the 98P4B6 (STEAP-2) gene to chromosome 7q21.
[0187] The following PCR primers were used for AI139607:
TABLE-US-00010 A1139607.1 5' TTAGGACAACTTGATCACCAGCA 3' (SEQ ID NO:
16) A1139607.2 5' TGTCCAGTCCAAACTGGGTTATTT 3' (SEQ ID NO: 17)
[0188] The resulting vector
(0000000010000000000000000000100010000020000000100010000
0001000000100010001010000010), and the mapping program available at
the internet address for the Stanford Human Genome Center, maps
AI139607 to chromosome 7q21.
[0189] The following PCR primers were used for R80991:
TABLE-US-00011 R80991.3 5'ACAAGAGCCACCTCTGGGTGAA 3' (SEQ ID NO: 31)
R80991.4 5'AGTTGAGCGAGTTTGCAATGGAC 3' (SEQ ID NO: 32)
[0190] The resulting vector
(00000000000200001020000000010000000000000000000010000
000001000011100000001001000001), and the mapping program available
at the internet address for the Stanford Human Genome Center, maps
R80991 to chromosome 2q14-q21, near D2S2591.
[0191] In summary, the above results show that three of the
putative human STEAP family members localize to chromosome 7, as is
schematically depicted in FIG. 17. In particular, the STEAP-1 gene
localizes to the far telomeric region of the short arm of
chromosome 7, at 7p22.3, while STEAP-2 and AI139607 localize to the
long arm of chromosome 7, at 7q21 (FIG. 17). R80991 maps to
chromosome 2q14-q21.
Example 8
Identification of Intron-Exon Boundaries of STEAP-1
[0192] Genomic clones for STEAP-1 were identified by searching
GenBank for BAC clones containing STEAP-1 sequences, resulting in
the identification of accession numbers AC004969 (PAC DJ1121E10)
and AC005053 (BAC RG041D11). Using the sequences derived from the
PAC and BAC clones for STEAP the intron-exon boundaries were
defined (FIG. 18). A total of 4 exons and 3 introns were identified
within the coding region of the STEAP gene. Knowledge of the exact
exon-intron structure of the STEAP-1 gene may be used for designing
primers within intronic sequences which in turn may be used for
genomic amplification of exons. Such amplification permits
single-stranded conformational polymorphism (SSCP) analysis to
search for polymorphisms associated with cancer. Mutant or
polymorphic exons may be sequenced and compared to wild type STEAP.
Such analysis may be useful to identify patients who are more
susceptible to aggressive prostate cancer, as well as other types
of cancer, particularly colon, bladder, pancreatic, ovarian,
cervical and testicular cancers.
[0193] Southern blot analysis shows that the STEAP-1 gene exists in
several species including mouse (FIG. 19). Therefore, a mouse BAC
library (Mouse ES 129-V release 1, Genome Systems, FRAC-4431) was
screened with the human cDNA for STEAP-1 (clone 10, Example 2). One
positive clone, 12P11, was identified and confirmed by southern
blotting (FIG. 20). The intron-exon boundary information for human
STEAP may be used to identify the mouse STEAP-1 coding
sequences.
[0194] The mouse STEAP-1 genomic clone may be used to study the
biological role of STEAP-1 during development and tumorigenesis.
Specifically, the mouse genomic STEAP-1 clone may be inserted into
a gene knock-out (K/O) vector for targeted disruption of the gene
in mice, using methods generally known in the art. In addition, the
role of STEAP in metabolic processes and epithelial cell function
may be elucidated. Such K/O mice may be crossed with other prostate
cancer mouse models, such as the TRAMP model (Greenberg et al.,
1995, PNAS 92:3439), to determine whether STEAP influences the
development and progression of more or less aggressive and
metastatic prostate cancers.
Example 9
Prediction of HLA-A2 Binding Peptides from STEAP-1 and STEAP-2
[0195] The complete amino acid sequences of the STEAP-1 and STEAP-2
proteins were entered into the HLA Peptide Motif Search algorithm
found in the Bioinformatics and Molecular Analysis Section (BIMAS)
Web site. The HLA Peptide Motif Search algorithm was developed by
Dr. Ken Parker based on binding of specific peptide sequences in
the groove of HLA Class I molecules and specifically HLA-A2 (Falk
et al., 1991, Nature 351: 290-6; Hunt et al., 1992, Science
255:1261-3; Parker et al., 1992, J. Immunol. 149:3580-7; Parker et
al., 1994, J. Immunol. 152:163-75). This algorithm allows location
and ranking of 8-mer, 9-mer, and 10-mer peptides from a complete
protein sequence for predicted binding to HLA-A2 as well as other
HLA Class I molecules. Most HLA-A2 binding peptides are 9-mers
favorably containing a leucine (L) at position 2 and a valine (V)
or leucine (L) at position 9.
[0196] The results of STEAP-1 and STEAP-2 predicted binding
peptides are shown in Table 2 below. For both proteins the top 5
ranking candidates are shown along with their location, the amino
acid sequence of each specific peptide, and an estimated binding
score. The binding score corresponds to the estimated half-time of
dissociation of complexes containing the peptide at 37.degree. C.
at pH 6.5. Peptides with the highest binding score (i.e. 10776.470
for STEAP-1 peptide 165; 1789.612 for STEAP-2 peptide 227) are
predicted to be the most tightly bound to HLA Class I on the cell
surface and thus represent the best immunogenic targets for T-cell
recognition. Actual binding of peptides to HLA-A2 can be evaluated
by stabilization of HLA-A2 expression on the antigen-processing
defective cell line T2 (Refs. 5,6). Immunogenicity of specific
peptides can be evaluated in vitro by stimulation of CD8+ cytotoxic
T lymphocytes (CTL) in the presence of dendritic cells (Xue et al.,
1997, Prostate 30:73-8; Peshwa et al., 1998, Prostate
36:129-38).
TABLE-US-00012 TABLE 2 Predicted Binding of STEAP-1 and STEAP-2
Peptide Sequences with Highest Affinity for HLA-A2 Score (Estimate
of Half Time of Start Subsequence Dissociation of Molecule Rank
Position Residue Listing Containing this Subsequence) STEAP-1 (SEQ
ID NO: 2) 1 165 GLLSFFFAV (SEQ ID NO: 36) 10776.470 2 86 FLYTLLREV
(SEQ ID NO: 37) 470.951 3 262 LLLGTIHAL (SEQ ID NO: 38) 309.050 4
302 LIFKSILFL (SEQ ID NO: 39) 233.719 5 158 MLTRKQFGL (SEQ ID NO:
40) 210.633 STEAP-2 (SEQ ID NO: 6) 1 227 FLYSFVRDV (SEQ ID NO: 41)
1789.612 2 402 ALLISTFHV (SEQ ID NO: 42) 1492.586 3 307 LLSFFFAMV
(SEQ ID NO: 43) 853.681 4 306 GLLSFFFAM (SEQ ID NO: 44) 769.748 5
100 SLWDLRHLL (SEQ ID NO: 45) 726.962
[0197] Throughout this application, various publications are
referenced within parentheses. The disclosures of these
publications are hereby incorporated by reference herein in their
entireties.
[0198] The present invention is not to be limited in scope by the
embodiments disclosed herein, which are intended as single
illustrations of individual aspects of the invention, and any which
are functionally equivalent are within the scope of the invention.
Various modifications to the models and methods of the invention,
in addition to those described herein, will become apparent to
those skilled in the art from the foregoing description and
teachings, and are similarly intended to fall within the scope of
the invention. Such modifications or other embodiments can be
practiced without departing from the true scope and spirit of the
invention.
Sequence CWU 1
1
4811193DNAHomo sapiensCDS(64)..(1080) 1gagactcacg gtcaagctaa
ggcgaagagt gggtggctga agccatacta ttttatagaa 60tta atg gaa agc aga
aaa gac atc aca aac caa gaa gaa ctt tgg aaa 108Met Glu Ser Arg Lys
Asp Ile Thr Asn Gln Glu Glu Leu Trp Lys1 5 10 15atg aag cct agg aga
aat tta gaa gaa gac gat tat ttg cat aag gac 156Met Lys Pro Arg Arg
Asn Leu Glu Glu Asp Asp Tyr Leu His Lys Asp 20 25 30acg gga gag acc
agc atg cta aaa aga cct gtg ctt ttg cat ttg cac 204Thr Gly Glu Thr
Ser Met Leu Lys Arg Pro Val Leu Leu His Leu His 35 40 45caa aca gcc
cat gct gat gaa ttt gac tgc cct tca gaa ctt cag cac 252Gln Thr Ala
His Ala Asp Glu Phe Asp Cys Pro Ser Glu Leu Gln His 50 55 60aca cag
gaa ctc ttt cca cag tgg cac ttg cca att aaa ata gct gct 300Thr Gln
Glu Leu Phe Pro Gln Trp His Leu Pro Ile Lys Ile Ala Ala 65 70 75att
ata gca tct ctg act ttt ctt tac act ctt ctg agg gaa gta att 348Ile
Ile Ala Ser Leu Thr Phe Leu Tyr Thr Leu Leu Arg Glu Val Ile80 85 90
95cac cct tta gca act tcc cat caa caa tat ttt tat aaa att cca atc
396His Pro Leu Ala Thr Ser His Gln Gln Tyr Phe Tyr Lys Ile Pro Ile
100 105 110ctg gtc atc aac aaa gtc ttg cca atg gtt tcc atc act ctc
ttg gca 444Leu Val Ile Asn Lys Val Leu Pro Met Val Ser Ile Thr Leu
Leu Ala 115 120 125ttg gtt tac ctg cca ggt gtg ata gca gca att gtc
caa ctt cat aat 492Leu Val Tyr Leu Pro Gly Val Ile Ala Ala Ile Val
Gln Leu His Asn 130 135 140gga acc aag tat aag aag ttt cca cat tgg
ttg gat aag tgg atg tta 540Gly Thr Lys Tyr Lys Lys Phe Pro His Trp
Leu Asp Lys Trp Met Leu 145 150 155aca aga aag cag ttt ggg ctt ctc
agt ttc ttt ttt gct gta ctg cat 588Thr Arg Lys Gln Phe Gly Leu Leu
Ser Phe Phe Phe Ala Val Leu His160 165 170 175gca att tat agt ctg
tct tac cca atg agg cga tcc tac aga tac aag 636Ala Ile Tyr Ser Leu
Ser Tyr Pro Met Arg Arg Ser Tyr Arg Tyr Lys 180 185 190ttg cta aac
tgg gca tat caa cag gtc caa caa aat aaa gaa gat gcc 684Leu Leu Asn
Trp Ala Tyr Gln Gln Val Gln Gln Asn Lys Glu Asp Ala 195 200 205tgg
att gag cat gat gtt tgg aga atg gag att tat gtg tct ctg gga 732Trp
Ile Glu His Asp Val Trp Arg Met Glu Ile Tyr Val Ser Leu Gly 210 215
220att gtg gga ttg gca ata ctg gct ctg ttg gct gtg aca tct att cca
780Ile Val Gly Leu Ala Ile Leu Ala Leu Leu Ala Val Thr Ser Ile Pro
225 230 235tct gtg agt gac tct ttg aca tgg aga gaa ttt cac tat att
cag agc 828Ser Val Ser Asp Ser Leu Thr Trp Arg Glu Phe His Tyr Ile
Gln Ser240 245 250 255aag cta gga att gtt tcc ctt cta ctg ggc aca
ata cac gca ttg att 876Lys Leu Gly Ile Val Ser Leu Leu Leu Gly Thr
Ile His Ala Leu Ile 260 265 270ttt gcc tgg aat aag tgg ata gat ata
aaa caa ttt gta tgg tat aca 924Phe Ala Trp Asn Lys Trp Ile Asp Ile
Lys Gln Phe Val Trp Tyr Thr 275 280 285cct cca act ttt atg ata gct
gtt ttc ctt cca att gtt gtc ctg ata 972Pro Pro Thr Phe Met Ile Ala
Val Phe Leu Pro Ile Val Val Leu Ile 290 295 300ttt aaa agc ata cta
ttc ctg cca tgc ttg agg aag aag ata ctg aag 1020Phe Lys Ser Ile Leu
Phe Leu Pro Cys Leu Arg Lys Lys Ile Leu Lys 305 310 315att aga cat
ggt tgg gaa gac gtc acc aaa att aac aaa act gag ata 1068Ile Arg His
Gly Trp Glu Asp Val Thr Lys Ile Asn Lys Thr Glu Ile320 325 330
335tgt tcc cag ttg tagaattact gtttacacac atttttgttc aatattgata
1120Cys Ser Gln Leutattttatca ccaacatttc aagtttgtat ttgttaataa
aatgattatt caaggaaaaa 1180aaaaaaaaaa aaa 11932339PRTHomo sapiens
2Met Glu Ser Arg Lys Asp Ile Thr Asn Gln Glu Glu Leu Trp Lys Met1 5
10 15Lys Pro Arg Arg Asn Leu Glu Glu Asp Asp Tyr Leu His Lys Asp
Thr 20 25 30Gly Glu Thr Ser Met Leu Lys Arg Pro Val Leu Leu His Leu
His Gln 35 40 45Thr Ala His Ala Asp Glu Phe Asp Cys Pro Ser Glu Leu
Gln His Thr 50 55 60Gln Glu Leu Phe Pro Gln Trp His Leu Pro Ile Lys
Ile Ala Ala Ile65 70 75 80Ile Ala Ser Leu Thr Phe Leu Tyr Thr Leu
Leu Arg Glu Val Ile His 85 90 95Pro Leu Ala Thr Ser His Gln Gln Tyr
Phe Tyr Lys Ile Pro Ile Leu 100 105 110Val Ile Asn Lys Val Leu Pro
Met Val Ser Ile Thr Leu Leu Ala Leu 115 120 125Val Tyr Leu Pro Gly
Val Ile Ala Ala Ile Val Gln Leu His Asn Gly 130 135 140Thr Lys Tyr
Lys Lys Phe Pro His Trp Leu Asp Lys Trp Met Leu Thr145 150 155
160Arg Lys Gln Phe Gly Leu Leu Ser Phe Phe Phe Ala Val Leu His Ala
165 170 175Ile Tyr Ser Leu Ser Tyr Pro Met Arg Arg Ser Tyr Arg Tyr
Lys Leu 180 185 190Leu Asn Trp Ala Tyr Gln Gln Val Gln Gln Asn Lys
Glu Asp Ala Trp 195 200 205Ile Glu His Asp Val Trp Arg Met Glu Ile
Tyr Val Ser Leu Gly Ile 210 215 220Val Gly Leu Ala Ile Leu Ala Leu
Leu Ala Val Thr Ser Ile Pro Ser225 230 235 240Val Ser Asp Ser Leu
Thr Trp Arg Glu Phe His Tyr Ile Gln Ser Lys 245 250 255Leu Gly Ile
Val Ser Leu Leu Leu Gly Thr Ile His Ala Leu Ile Phe 260 265 270Ala
Trp Asn Lys Trp Ile Asp Ile Lys Gln Phe Val Trp Tyr Thr Pro 275 280
285Pro Thr Phe Met Ile Ala Val Phe Leu Pro Ile Val Val Leu Ile Phe
290 295 300Lys Ser Ile Leu Phe Leu Pro Cys Leu Arg Lys Lys Ile Leu
Lys Ile305 310 315 320Arg His Gly Trp Glu Asp Val Thr Lys Ile Asn
Lys Thr Glu Ile Cys 325 330 335Ser Gln Leu3111DNAHomo sapiens
3ggcggaggcg gaggcggagg gcgaggggcg gggagcgccg cctggagcgc ggcaggtcat
60attgaacatt ccagatacct atcattactc gatgctgttg ataacagcaa g
11143627DNAHomo sapiens 4ggggcccgca cctctgggca gcagcggcag
ccgagactca cggtcaagct aaggcgaaga 60gtgggtggct gaagccatac tattttatag
aattaatgga aagcagaaaa gacatcacaa 120accaagaaga actttggaaa
atgaagccta ggagaaattt agaagaagac gattatttgc 180ataaggacac
gggagagacc agcatgctaa aaagacctgt gcttttgcat ttgcaccaaa
240cagcccatgc tgatgaattt gactgccctt cagaacttca gcacacacag
gaactctttc 300cacagtggca cttgccaatt aaaatagctg ctattatagc
atctctgact tttctttaca 360ctcttctgag ggaagtaatt caccccttag
caacttccca tcaacaatat ttttataaaa 420ttccaatcct ggtcatcaac
aaagtcttgc caatggtttc catcactctc ttggcattgg 480tttacctgcc
aggtgtgata gcagcaattg tccaacttca taatggaacc aagtataaga
540agtttccaca ttggttggat aagtggatgt taacaagaaa gcagtttggg
cttctcagtt 600tcttttttgc tgtactgcat gcaatttata gtctgtctta
cccaatgagg cgatcctaca 660gatacaagtt gctaaactgg gcatatcaac
aggtccaaca aaataaagaa gatgcctgga 720ttgagcatga tgtttggaga
atggagattt atgtgtctct gggaattgtg ggattggcaa 780tactggctct
gttggctgtg acatctattc catctgtgag tgactctttg acatggagag
840aatttcacta tattcaggta aataatatat aaaataaccc taagaggtaa
atcttctttt 900tgtgtttatg atatagaata tgttgacttt accccataaa
aaataacaaa tgtttttcaa 960cagcaaagat cttatacttg ttccaattaa
taatgtgctc tcctgttgtt ttccctattg 1020cttctaatta ggacaagtgt
ttcctagaca taaataaaag gcattaaaat attctttgtt 1080tttttttttt
tgtttgtttg ttttttgttt gtttgtttgt ttttttgaga tgaagtctcg
1140ctctgttgcc catgctggag tacagtggca cgatctcggc tcactgcaac
ctgcgcctcc 1200tgggttcagg cgattctctt gcctcagcct cctgagtagc
tgggattaca ggcacccatc 1260accatgtcca gctaattttt gtatttttag
tagagacagg gttttcccat gttggccagg 1320ctggtctcga tctcctgacc
tcaaatgatc cgcccacctc ggcctcccaa agtgctggga 1380tgacagttgt
gagccaccac actcagcctg ctctttctaa tatttgaaac ttgttagaca
1440atttgctacc catctaatgt gatattttag gaatccaata tgcatggttt
attatttctt 1500aaaaaaaata ttcttttacc tgtcacctga atttagtaat
gccttttatg ttacacaact 1560tagcactttc cagaaacaaa aactctctcc
ttgaaataat agagttttta tctaccaaag 1620atatgctagt gtctcatttc
aaaggctgct ttttccagct tacattttat atacttactc 1680acttgaagtt
tctaaatatt cttgtaattt taaaactatc tcagatttac tgaggtttat
1740cttctggtgg tagattatcc ataagaagag tgatgtgcca gaatcactct
gggatccttg 1800tctgacaaga ttcaaaggac taaatttaat tcagtcatga
acactgccaa ttaccgttta 1860tgggtagaca tctttggaaa tttccacaag
gtcagacatt cgcaactatc ccttctacat 1920gtccacacgt atactccaac
actttattag gcatctgatt agtttggaaa gtatgcctcc 1980atctgaatta
gtccagtgtg gcttagagtt ggtacaacat tctcacagaa tttcctaatt
2040ttgtaggttc agcctgataa ccactggagt tctttggtcc tcattaaata
gctttcttca 2100cacattgctc tgcctgttac acatatgatg aacactgctt
tttagacttc attaggaatt 2160taggactgca tcttgacaac tgagcctatt
ctactatatg tacaatacct agcccataat 2220aggtatacaa tacacatttg
gtaaaactaa ttttcaacca atgacatgta tttttcaact 2280agtaacctag
aaatgtttca cttaaaatct gagaactggt tacactacaa gttaccttgg
2340agattcatat atgaaaacgc aaacttagct atttgattgt attcactggg
acttaagaat 2400gcgcctgaat aattgtgagt tcgatttgtt ctggcaggct
aatgaccatt tccagtaaag 2460tgaatagagg tcagaagtcg tataaaagag
gtgttgtcag aacaccgttg agattacata 2520ggtgaacaac tatttttaag
caactttatt tgtgtagtga caaagcatcc caatgcaggc 2580tgaaatgttt
catcacatct ctggatctct ctattttgtg cagacattga aaaaattgtt
2640catattattt ccatgttatc agaatatttg attttttaaa aacataggcc
aagttcattc 2700acttcattat tcatttatca aaatcagagt gaatcacatt
agtcgccttc acaactgata 2760aagatcactg aagtcaaatt gatttttgct
ataatcttca atctacctat atttaattga 2820gaatctaaaa tgtacaaatc
attgtgttga ttctgcagtg atcctgctat aagtaagact 2880cagtccctga
ttttaggtat cctgtgaaaa gcagaattaa gacaaataca caagagacaa
2940agcacaaaaa ataaatatca taaggggatg aacaaaatgg tggagaaaga
gtagacaaag 3000tttttgatca cctgccttca aagaaaggct gtgaattttg
ttcacttaga cagcttggag 3060acaagaaatt acccaaaagt aaggtgagga
ggataggcaa aaagagcaga aagatgtgaa 3120tggacattgt tgagaaatgt
gataggaaaa caatcataga taaaggattt ccaagcaaca 3180gagcatatcc
agatgaggta ggatgggata aactcttatt gaaccaatct tcaccaattt
3240tgtttttctt ttgcagagca agctaggaat tgtttccctt ctactgggca
caatacacgc 3300attgattttt gcctggaata agtggataga tataaaacaa
tttgtatggt atacacctcc 3360aacttttatg atagctgttt tccttccaat
tgttgtcctg atatttaaaa gcatactatt 3420cctgccatgc ttgaggaaga
agatactgaa gattagacat ggttgggaag acgtcaccaa 3480aattaacaaa
actgagatat gttcccagtt gtagaattac tgtttacaca catttttgtt
3540caatattgat atattttatc accaacattt caagtttgta tttgttaata
aaatgattat 3600tcaaggaaaa aaaaaaaaaa aaaaaaa 362752453DNAHomo
sapiensCDS(355)..(1716) 5ggacgcgtgg gcggacgcgt gggttcctcg
ggccctcggc gccacaagct gtccgggcac 60gcagccccta gcggcgcgtc gctgccaagc
cggcctccgc gcgcctccct ccttccttct 120cccctggctg ttcgcgatcc
agcttgggta ggcggggaag cagctggagt gcgaccgcca 180cggcagccac
cctgcaaccg ccagtcggag gtgcagtccg taggccctgg cccccgggtg
240ggcccttggg gagtcggcgc cgctcccgag gagctgcaag gctcgcccct
gcccggcgtg 300gagggcgcgg ggggcgcgga ggatattctt ggtgatcttg
gaagtgtccg tatc atg 357Met1gaa tca atc tct atg atg gga agc cct aag
agc ctt agt gaa act tgt 405Glu Ser Ile Ser Met Met Gly Ser Pro Lys
Ser Leu Ser Glu Thr Cys 5 10 15tta cct aat ggc ata aat ggt atc aaa
gat gca agg aag gtc act gta 453Leu Pro Asn Gly Ile Asn Gly Ile Lys
Asp Ala Arg Lys Val Thr Val 20 25 30ggt gtg att gga agt gga gat ttt
gcc aaa tcc ttg acc att cga ctt 501Gly Val Ile Gly Ser Gly Asp Phe
Ala Lys Ser Leu Thr Ile Arg Leu 35 40 45att aga tgc ggc tat cat gtg
gtc ata gga agt aga aat cct aag ttt 549Ile Arg Cys Gly Tyr His Val
Val Ile Gly Ser Arg Asn Pro Lys Phe50 55 60 65gct tct gaa ttt ttt
cct cat gtg gta gat gtc act cat cat gaa gat 597Ala Ser Glu Phe Phe
Pro His Val Val Asp Val Thr His His Glu Asp 70 75 80gct ctc aca aaa
aca aat ata ata ttt gtt gct ata cac aga gaa cat 645Ala Leu Thr Lys
Thr Asn Ile Ile Phe Val Ala Ile His Arg Glu His 85 90 95tat acc tcc
ctg tgg gac ctg aga cat ctg ctt gtg ggt aaa atc ctg 693Tyr Thr Ser
Leu Trp Asp Leu Arg His Leu Leu Val Gly Lys Ile Leu 100 105 110att
gat gtg agc aat aac atg agg ata aac cag tac cca gaa tcc aat 741Ile
Asp Val Ser Asn Asn Met Arg Ile Asn Gln Tyr Pro Glu Ser Asn 115 120
125gct gaa tat ttg gct tca tta ttc cca gat tct ttg att gtc aaa gga
789Ala Glu Tyr Leu Ala Ser Leu Phe Pro Asp Ser Leu Ile Val Lys
Gly130 135 140 145ttt aat gtt gtc tca gct tgg gca ctt cag tta gga
cct aag gat gcc 837Phe Asn Val Val Ser Ala Trp Ala Leu Gln Leu Gly
Pro Lys Asp Ala 150 155 160agc cgg cag gtt tat ata tgc agc aac aat
att caa gcg cga caa cag 885Ser Arg Gln Val Tyr Ile Cys Ser Asn Asn
Ile Gln Ala Arg Gln Gln 165 170 175gtt att gaa ctt gcc cgc cag ttg
aat ttc att ccc att gac ttg gga 933Val Ile Glu Leu Ala Arg Gln Leu
Asn Phe Ile Pro Ile Asp Leu Gly 180 185 190tcc tta tca tca gcc aga
gag att gaa aat tta ccc cta cga ctc ttt 981Ser Leu Ser Ser Ala Arg
Glu Ile Glu Asn Leu Pro Leu Arg Leu Phe 195 200 205act ctc tgg aga
ggg cca gtg gtg gta gct ata agc ttg gcc aca ttt 1029Thr Leu Trp Arg
Gly Pro Val Val Val Ala Ile Ser Leu Ala Thr Phe210 215 220 225ttt
ttc ctt tat tcc ttt gtc aga gat gtg att cat cca tat gct aga 1077Phe
Phe Leu Tyr Ser Phe Val Arg Asp Val Ile His Pro Tyr Ala Arg 230 235
240aac caa cag agt gac ttt tac aaa att cct ata gag att gtg aat aaa
1125Asn Gln Gln Ser Asp Phe Tyr Lys Ile Pro Ile Glu Ile Val Asn Lys
245 250 255acc tta cct ata gtt gcc att act ttg ctc tcc cta gta tac
ctt gca 1173Thr Leu Pro Ile Val Ala Ile Thr Leu Leu Ser Leu Val Tyr
Leu Ala 260 265 270ggt ctt ctg gca gct gct tat caa ctt tat tac ggc
acc aag tat agg 1221Gly Leu Leu Ala Ala Ala Tyr Gln Leu Tyr Tyr Gly
Thr Lys Tyr Arg 275 280 285aga ttt cca cct tgg ttg gaa acc tgg tta
cag tgt aga aaa cag ctt 1269Arg Phe Pro Pro Trp Leu Glu Thr Trp Leu
Gln Cys Arg Lys Gln Leu290 295 300 305gga tta cta agt ttt ttc ttc
gct atg gtc cat gtt gcc tac agc ctc 1317Gly Leu Leu Ser Phe Phe Phe
Ala Met Val His Val Ala Tyr Ser Leu 310 315 320tgc tta ccg atg aga
agg tca gag aga tat ttg ttt ctc aac atg gct 1365Cys Leu Pro Met Arg
Arg Ser Glu Arg Tyr Leu Phe Leu Asn Met Ala 325 330 335tat cag cag
gtt cat gca aat att gaa aac tct tgg aat gag gaa gaa 1413Tyr Gln Gln
Val His Ala Asn Ile Glu Asn Ser Trp Asn Glu Glu Glu 340 345 350gtt
tgg aga att gaa atg tat atc tcc ttt ggc ata atg agc ctt ggc 1461Val
Trp Arg Ile Glu Met Tyr Ile Ser Phe Gly Ile Met Ser Leu Gly 355 360
365tta ctt tcc ctc ctg gca gtc act tct atc cct tca gtg agc aat gct
1509Leu Leu Ser Leu Leu Ala Val Thr Ser Ile Pro Ser Val Ser Asn
Ala370 375 380 385tta aac tgg aga gaa ttc agt ttt att cag tct aca
ctt gga tat gtc 1557Leu Asn Trp Arg Glu Phe Ser Phe Ile Gln Ser Thr
Leu Gly Tyr Val 390 395 400gct ctg ctc ata agt act ttc cat gtt tta
att tat gga tgg aaa cga 1605Ala Leu Leu Ile Ser Thr Phe His Val Leu
Ile Tyr Gly Trp Lys Arg 405 410 415gct ttt gag gaa gag tac tac aga
ttt tat aca cca cca aac ttt gtt 1653Ala Phe Glu Glu Glu Tyr Tyr Arg
Phe Tyr Thr Pro Pro Asn Phe Val 420 425 430ctt gct ctt gtt ttg ccc
tca att gta att ctg gat ctt ttg cag ctt 1701Leu Ala Leu Val Leu Pro
Ser Ile Val Ile Leu Asp Leu Leu Gln Leu 435 440 445tgc aga tac cca
gac tgagctggaa ctggaatttg tcttcctatt gactctactt 1756Cys Arg Tyr Pro
Asp450ctttaaaagc ggctgcccat tacattcctc agctgtcctt gcagttaggt
gtacatgtga 1816ctgagtgttg gccagtgaga tgaagtctcc tcaaaggaag
gcagcatgtg tcctttttca 1876tcccttcatc ttgctgctgg gattgtggat
ataacaggag ccctggcagc tgtctccaga 1936ggatcaaagc cacacccaaa
gagtaaggca gattagagac cagaaagacc ttgactactt 1996ccctacttcc
actgcttttc ctgcatttaa gccattgtaa atctgggtgt gttacatgaa
2056gtgaaaatta attctttctg cccttcagtt ctttatcctg ataccattta
acactgtctg 2116aattaactag actgcaataa ttctttcttt tgaaagcttt
taaaggataa tgtgcaattc 2176acattaaaat tgattttcca ttgtcaatta
gttatactca ttttcctgcc ttgatctttc 2236attagatatt ttgtatctgc
ttggaatata ttatcttctt tttaactgtg taattggtaa 2296ttactaaaac
tctgtaatct ccaaaatatt gctatcaaat tacacaccat gttttctatc
2356attctcatag atctgcctta taaacattta aataaaaagt actatttaat
gatttaaaaa 2416aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa
24536454PRTHomo sapiens 6Met Glu Ser Ile Ser Met
Met Gly Ser Pro Lys Ser Leu Ser Glu Thr1 5 10 15Cys Leu Pro Asn Gly
Ile Asn Gly Ile Lys Asp Ala Arg Lys Val Thr 20 25 30Val Gly Val Ile
Gly Ser Gly Asp Phe Ala Lys Ser Leu Thr Ile Arg 35 40 45Leu Ile Arg
Cys Gly Tyr His Val Val Ile Gly Ser Arg Asn Pro Lys 50 55 60Phe Ala
Ser Glu Phe Phe Pro His Val Val Asp Val Thr His His Glu65 70 75
80Asp Ala Leu Thr Lys Thr Asn Ile Ile Phe Val Ala Ile His Arg Glu
85 90 95His Tyr Thr Ser Leu Trp Asp Leu Arg His Leu Leu Val Gly Lys
Ile 100 105 110Leu Ile Asp Val Ser Asn Asn Met Arg Ile Asn Gln Tyr
Pro Glu Ser 115 120 125Asn Ala Glu Tyr Leu Ala Ser Leu Phe Pro Asp
Ser Leu Ile Val Lys 130 135 140Gly Phe Asn Val Val Ser Ala Trp Ala
Leu Gln Leu Gly Pro Lys Asp145 150 155 160Ala Ser Arg Gln Val Tyr
Ile Cys Ser Asn Asn Ile Gln Ala Arg Gln 165 170 175Gln Val Ile Glu
Leu Ala Arg Gln Leu Asn Phe Ile Pro Ile Asp Leu 180 185 190Gly Ser
Leu Ser Ser Ala Arg Glu Ile Glu Asn Leu Pro Leu Arg Leu 195 200
205Phe Thr Leu Trp Arg Gly Pro Val Val Val Ala Ile Ser Leu Ala Thr
210 215 220Phe Phe Phe Leu Tyr Ser Phe Val Arg Asp Val Ile His Pro
Tyr Ala225 230 235 240Arg Asn Gln Gln Ser Asp Phe Tyr Lys Ile Pro
Ile Glu Ile Val Asn 245 250 255Lys Thr Leu Pro Ile Val Ala Ile Thr
Leu Leu Ser Leu Val Tyr Leu 260 265 270Ala Gly Leu Leu Ala Ala Ala
Tyr Gln Leu Tyr Tyr Gly Thr Lys Tyr 275 280 285Arg Arg Phe Pro Pro
Trp Leu Glu Thr Trp Leu Gln Cys Arg Lys Gln 290 295 300Leu Gly Leu
Leu Ser Phe Phe Phe Ala Met Val His Val Ala Tyr Ser305 310 315
320Leu Cys Leu Pro Met Arg Arg Ser Glu Arg Tyr Leu Phe Leu Asn Met
325 330 335Ala Tyr Gln Gln Val His Ala Asn Ile Glu Asn Ser Trp Asn
Glu Glu 340 345 350Glu Val Trp Arg Ile Glu Met Tyr Ile Ser Phe Gly
Ile Met Ser Leu 355 360 365Gly Leu Leu Ser Leu Leu Ala Val Thr Ser
Ile Pro Ser Val Ser Asn 370 375 380Ala Leu Asn Trp Arg Glu Phe Ser
Phe Ile Gln Ser Thr Leu Gly Tyr385 390 395 400Val Ala Leu Leu Ile
Ser Thr Phe His Val Leu Ile Tyr Gly Trp Lys 405 410 415Arg Ala Phe
Glu Glu Glu Tyr Tyr Arg Phe Tyr Thr Pro Pro Asn Phe 420 425 430Val
Leu Ala Leu Val Leu Pro Ser Ile Val Ile Leu Asp Leu Leu Gln 435 440
445Leu Cys Arg Tyr Pro Asp 45074429DNAHomo sapiensCDS(85)..(1461)
7cgaaacttcc ctctacccgc ccggcccgcg gcgcgcaccg ttggcgctgg acgcttcctc
60cttggaagcg cctctccctc agtt atg gag aaa act tgt ata gat gca ctt
111Met Glu Lys Thr Cys Ile Asp Ala Leu1 5cct ctt act atg aat tct
tca gaa aag caa gag act gta tgt att ttt 159Pro Leu Thr Met Asn Ser
Ser Glu Lys Gln Glu Thr Val Cys Ile Phe10 15 20 25gga act ggt gat
ttt gga aga tca ctg gga ttg aaa atg ctc cag tgt 207Gly Thr Gly Asp
Phe Gly Arg Ser Leu Gly Leu Lys Met Leu Gln Cys 30 35 40ggt tat tct
gtt gtt ttt gga agt cga aac ccc cag aag acc acc cta 255Gly Tyr Ser
Val Val Phe Gly Ser Arg Asn Pro Gln Lys Thr Thr Leu 45 50 55ctg ccc
agt ggt gca gaa gtc ttg agc tat tca gaa gca gcc aag aag 303Leu Pro
Ser Gly Ala Glu Val Leu Ser Tyr Ser Glu Ala Ala Lys Lys 60 65 70tct
ggc atc ata atc ata gca atc cac aga gag cat tat gat ttt ctc 351Ser
Gly Ile Ile Ile Ile Ala Ile His Arg Glu His Tyr Asp Phe Leu 75 80
85aca gaa tta act gag gtt ctc aat gga aaa ata ttg gta gac atc agc
399Thr Glu Leu Thr Glu Val Leu Asn Gly Lys Ile Leu Val Asp Ile
Ser90 95 100 105aac aac ctc aaa atc aat caa tat cca gaa tct aat gca
gag tac ctt 447Asn Asn Leu Lys Ile Asn Gln Tyr Pro Glu Ser Asn Ala
Glu Tyr Leu 110 115 120gct cat ttg gtg cca gga gcc cac gtg gta aaa
gca ttt aac acc atc 495Ala His Leu Val Pro Gly Ala His Val Val Lys
Ala Phe Asn Thr Ile 125 130 135tca gcc tgg gct ctc cag tca gga gca
ctg gat gca agt cgg cag gtg 543Ser Ala Trp Ala Leu Gln Ser Gly Ala
Leu Asp Ala Ser Arg Gln Val 140 145 150ttt gtg tgt gga aat gac agc
aaa gcc aag caa aga gtg atg gat att 591Phe Val Cys Gly Asn Asp Ser
Lys Ala Lys Gln Arg Val Met Asp Ile 155 160 165gtt cgt aat ctt gga
ctt act cca atg gat caa gga tca ctc atg gca 639Val Arg Asn Leu Gly
Leu Thr Pro Met Asp Gln Gly Ser Leu Met Ala170 175 180 185gcc aaa
gaa att gaa aag tac ccc ctg cag cta ttt cca atg tgg agg 687Ala Lys
Glu Ile Glu Lys Tyr Pro Leu Gln Leu Phe Pro Met Trp Arg 190 195
200ttc ccc ttc tat ttg tct gct gtg ctg tgt gtc ttc ttg ttt ttc tat
735Phe Pro Phe Tyr Leu Ser Ala Val Leu Cys Val Phe Leu Phe Phe Tyr
205 210 215tgt gtt ata aga gac gta atc tac cct tat gtt tat gaa aag
aaa gat 783Cys Val Ile Arg Asp Val Ile Tyr Pro Tyr Val Tyr Glu Lys
Lys Asp 220 225 230aat aca ttt cgt atg gct att tcc att cca aat cgt
atc ttt cca ata 831Asn Thr Phe Arg Met Ala Ile Ser Ile Pro Asn Arg
Ile Phe Pro Ile 235 240 245aca gca ctt aca ctg ctt gct ttg gtt tac
ctc cct ggt gtt att gct 879Thr Ala Leu Thr Leu Leu Ala Leu Val Tyr
Leu Pro Gly Val Ile Ala250 255 260 265gcc att cta caa ctg tac cga
ggc aca aaa tac cgt cga ttc cca gac 927Ala Ile Leu Gln Leu Tyr Arg
Gly Thr Lys Tyr Arg Arg Phe Pro Asp 270 275 280tgg ctt gac cac tgg
atg ctt tgc cga aag cag ctt ggc ttg gta gct 975Trp Leu Asp His Trp
Met Leu Cys Arg Lys Gln Leu Gly Leu Val Ala 285 290 295ctg gga ttt
gcc ttc ctt cat gtc ctc tac aca ctt gtg att cct att 1023Leu Gly Phe
Ala Phe Leu His Val Leu Tyr Thr Leu Val Ile Pro Ile 300 305 310cga
tat tat gta cga tgg aga ttg gga aac tta acc gtt acc cag gca 1071Arg
Tyr Tyr Val Arg Trp Arg Leu Gly Asn Leu Thr Val Thr Gln Ala 315 320
325ata ctc aag aag gag aat cca ttt agc acc tcc tca gcc tgg ctc agt
1119Ile Leu Lys Lys Glu Asn Pro Phe Ser Thr Ser Ser Ala Trp Leu
Ser330 335 340 345gat tca tat gtg gct ttg gga ata ctt ggg ttt ttt
ctg ttt gta ctc 1167Asp Ser Tyr Val Ala Leu Gly Ile Leu Gly Phe Phe
Leu Phe Val Leu 350 355 360ttg gga atc act tct ttg cca tct gtt agc
aat gca gtc aac tgg aga 1215Leu Gly Ile Thr Ser Leu Pro Ser Val Ser
Asn Ala Val Asn Trp Arg 365 370 375gag ttc cga ttt gtc cag tcc aaa
ctg ggt tat ttg acc ctg atc ttg 1263Glu Phe Arg Phe Val Gln Ser Lys
Leu Gly Tyr Leu Thr Leu Ile Leu 380 385 390tgt aca gcc cac acc ctg
gtg tac ggt ggg aag aga ttc ctc agc cct 1311Cys Thr Ala His Thr Leu
Val Tyr Gly Gly Lys Arg Phe Leu Ser Pro 395 400 405tca aat ctc aga
tgg tat ctt cct gca gcc tac gtg tta ggg ctt atc 1359Ser Asn Leu Arg
Trp Tyr Leu Pro Ala Ala Tyr Val Leu Gly Leu Ile410 415 420 425att
cct tgc act gtg ctg gtg atc aag ttt gtc cta atc atg cca tgt 1407Ile
Pro Cys Thr Val Leu Val Ile Lys Phe Val Leu Ile Met Pro Cys 430 435
440gta gac aac acc ctt aca agg atc cgc cag ggc tgg gaa agg aac tca
1455Val Asp Asn Thr Leu Thr Arg Ile Arg Gln Gly Trp Glu Arg Asn Ser
445 450 455aaa cac tagaaaaagc attgaatgga aaatcaatat ttaaaacaaa
gttcaattta 1511Lys Hisgctggatttc tgaactatgg ttttgaatgt ttaaagaaga
atgatgggta cagttaggaa 1571agtttttttc ttacaccgtg actgagggaa
acattgcttg tctttgagaa attgactgac 1631atactggaag agaacaccat
tttatctcag gttagtgaag aatcagtgca ggtccctgac 1691tcttattttc
ccagaggcca tggagctgag attgagacta gccttgtggt ttcacactaa
1751agagtttcct tgttatgggc aacatgcatg acctaatgtc ttgcaaaatc
caatagaagt 1811attgcagctt ccttctctgg ctcaagggct gagttaagtg
aaaggaaaaa cagcacaatg 1871gtgaccactg ataaaggctt tattaggtat
atctgaggaa gtgggtcaca tgaaatgtaa 1931aaagggaatg aggtttttgt
tgttttttgg aagtaaaggc aaacataaat attaccatga 1991tgaattctag
tgaaatgacc ccttgacttt gcttttctta atacagatat ttactgagag
2051gaactatttt tataacacaa gaaaaattta caattgatta aaagtatcca
tgtcttggat 2111acatacgtat ctatagagct ggcatgtaat tcttcctcta
taaagaatag gtataggaaa 2171gactgaataa aaatggaggg atatcccctt
ggatttcact tgcattgtgc aataagcaaa 2231gaagggttga taaaagttct
tgatcaaaaa gttcaaagaa accagaattt tagacagcaa 2291gctaaataaa
tattgtaaaa ttgcactata ttaggttaag tattatttag gtattataat
2351atgctttgta aattttatat tccaaatatt gctcaatatt tttcatctat
taaattaatt 2411tctagtgtaa ataagtagct tctatatctg tcttagtcta
ttataattgt aaggagtaaa 2471attaaatgaa tagtctgcag gtataaattt
gaacaatgca tagatgatcg aaaattacgg 2531aaaatcatag ggcagagagg
tgtgaagatt catcattatg tgaaatttgg atctttctca 2591aatccttgct
gaaatttagg atggttctca ctgtttttct gtgctgatag taccctttcc
2651aaggtgacct tcagggggat taaccttcct agctcaagca atgagctaaa
aggagcctta 2711tgcatgatct tcccacatat caaaataact aaaaggcact
gagtttggca tttttctgcc 2771tgctctgcta agaccttttt ttttttttta
ctttcattat aacatattat acatgacatt 2831atacaaaaat gattaaaata
tattaaaaca acatcaacaa tccaggatat ttttctataa 2891aactttttaa
aaataattgt atctatatat tcaattttac atcctttttc aaaggctttg
2951tttttctaaa ggctttgttt tcctttttat tatttttttc ttttttattt
ttttgagaca 3011gtcttgctct gtcgctcagg ctggagtgca gtggcacgat
ctcagctcac tgcaacctcc 3071tcctcccagg ttcaagtgat tcttgttcat
cagcctcccg agtagctggg actacaggca 3131tgtgccacta tgcccagcta
atttttgtac ttttagtaga gacagggttt caccacattg 3191gtcaggctgg
tcttgaaatg ctggcgtcaa gtgatctgcc tgcctccgcc ttacgtaata
3251tattttctta atggctgcat aatatcacat caaataggca tttttcaaac
ctctttcctt 3311attaaacatg tagactatat ccatttttta ctaaaataaa
taacatttca gataatatct 3371ttgcactgat aatgttgcca agccatttct
aaagtgacct tatcaattta attaccattg 3431gatgagggtg ttgctttcat
cgcaccattg tagattgtct tttttatttc aatttgcgtt 3491tatttataac
tggttgcaaa ggtacacaga acacacgctc cttcaactta tctttgataa
3551acccaagcaa ggatacaaaa agttggacga cattgagtag agtcatggta
tacggtgctg 3611accctacagt atcagtggaa aagataagga aaatgtcact
actcacctat gttatgcaaa 3671acagttaggt gtgctggggc tggatactgc
tcttttactt gagcattggt tgattaaagt 3731ttaggtacca tccaggctgg
tctagagaag tctttggagt taaccatgct ctttttgtta 3791aagaagagag
taatgtgttt atcctggctc atagtccgtc accgaaaata gaaaatgcca
3851tccataggta aaatgctgac ctatagaaaa aaatgaactc tacttttata
gcctagtaaa 3911aatgctctac ctgagtagtt aaaagcaatt catgaagcct
gaagctaaag agcactctga 3971tggttttggc ataatagctg catttccaga
cctgaccttt ggccccaacc acaagtgctc 4031caagccccac cagctgacca
aagaaagccc aagttctcct tctgtccttc ccacaacctc 4091cctgctccca
aaactatgaa attaatttga ccatattaac acagctgact cctccagttt
4151acttaaggta gaaagaatga gtttacaaca gatgaaaata agtgctttgg
gcgaactgta 4211ttccttttaa cagatccaaa ctattttaca tttaaaaaaa
aagttaaact aaacttcttt 4271actgctgata tgtttcctgt attctagaaa
aatttttaca ctttcacatt atttttgtac 4331actttcccca tgttaaggga
tgatggcttt tataaatgtg tattcattaa atgttacttt 4391aaaaataaaa
aaaaaaaaaa aaaaaaaaaa aaaaaaaa 44298459PRTHomo sapiens 8Met Glu Lys
Thr Cys Ile Asp Ala Leu Pro Leu Thr Met Asn Ser Ser1 5 10 15Glu Lys
Gln Glu Thr Val Cys Ile Phe Gly Thr Gly Asp Phe Gly Arg 20 25 30Ser
Leu Gly Leu Lys Met Leu Gln Cys Gly Tyr Ser Val Val Phe Gly 35 40
45Ser Arg Asn Pro Gln Lys Thr Thr Leu Leu Pro Ser Gly Ala Glu Val
50 55 60Leu Ser Tyr Ser Glu Ala Ala Lys Lys Ser Gly Ile Ile Ile Ile
Ala65 70 75 80Ile His Arg Glu His Tyr Asp Phe Leu Thr Glu Leu Thr
Glu Val Leu 85 90 95Asn Gly Lys Ile Leu Val Asp Ile Ser Asn Asn Leu
Lys Ile Asn Gln 100 105 110Tyr Pro Glu Ser Asn Ala Glu Tyr Leu Ala
His Leu Val Pro Gly Ala 115 120 125His Val Val Lys Ala Phe Asn Thr
Ile Ser Ala Trp Ala Leu Gln Ser 130 135 140Gly Ala Leu Asp Ala Ser
Arg Gln Val Phe Val Cys Gly Asn Asp Ser145 150 155 160Lys Ala Lys
Gln Arg Val Met Asp Ile Val Arg Asn Leu Gly Leu Thr 165 170 175Pro
Met Asp Gln Gly Ser Leu Met Ala Ala Lys Glu Ile Glu Lys Tyr 180 185
190Pro Leu Gln Leu Phe Pro Met Trp Arg Phe Pro Phe Tyr Leu Ser Ala
195 200 205Val Leu Cys Val Phe Leu Phe Phe Tyr Cys Val Ile Arg Asp
Val Ile 210 215 220Tyr Pro Tyr Val Tyr Glu Lys Lys Asp Asn Thr Phe
Arg Met Ala Ile225 230 235 240Ser Ile Pro Asn Arg Ile Phe Pro Ile
Thr Ala Leu Thr Leu Leu Ala 245 250 255Leu Val Tyr Leu Pro Gly Val
Ile Ala Ala Ile Leu Gln Leu Tyr Arg 260 265 270Gly Thr Lys Tyr Arg
Arg Phe Pro Asp Trp Leu Asp His Trp Met Leu 275 280 285Cys Arg Lys
Gln Leu Gly Leu Val Ala Leu Gly Phe Ala Phe Leu His 290 295 300Val
Leu Tyr Thr Leu Val Ile Pro Ile Arg Tyr Tyr Val Arg Trp Arg305 310
315 320Leu Gly Asn Leu Thr Val Thr Gln Ala Ile Leu Lys Lys Glu Asn
Pro 325 330 335Phe Ser Thr Ser Ser Ala Trp Leu Ser Asp Ser Tyr Val
Ala Leu Gly 340 345 350Ile Leu Gly Phe Phe Leu Phe Val Leu Leu Gly
Ile Thr Ser Leu Pro 355 360 365Ser Val Ser Asn Ala Val Asn Trp Arg
Glu Phe Arg Phe Val Gln Ser 370 375 380Lys Leu Gly Tyr Leu Thr Leu
Ile Leu Cys Thr Ala His Thr Leu Val385 390 395 400Tyr Gly Gly Lys
Arg Phe Leu Ser Pro Ser Asn Leu Arg Trp Tyr Leu 405 410 415Pro Ala
Ala Tyr Val Leu Gly Leu Ile Ile Pro Cys Thr Val Leu Val 420 425
430Ile Lys Phe Val Leu Ile Met Pro Cys Val Asp Asn Thr Leu Thr Arg
435 440 445Ile Arg Gln Gly Trp Glu Arg Asn Ser Lys His 450
4559322DNAHomo sapiens 9ggtcgacttt tcctttattc ctttgtcaga gatctgattc
atccatatgc tagaaaccaa 60cagagtgact tttacaaaat tcctatagag attgtgaata
aaaccttacc tatagttgcc 120attactttgc tctccctagt ataccttgca
ggtcttctgg cagctgctta tcaactttat 180tacggcacca agtataggag
atttccacct tggttggaaa cctggttaca gtgtagaaaa 240cagcttggat
tactaagttg tttcttcgct atggtccatg ttgcctacag cctctgctta
300ccgatgagaa ggtcagagag at 32210183DNAHomo sapiens 10tttgcagctt
tgcagatacc cagactgagc tggaactgga atttgtcttc ctattgactc 60tacttcttta
aaagcggctg cccattacat tcctcagctg tccttgcagt taggtgtaca
120tgtgactgag tgttggccag tgagatgaag tctcctcaaa ggaaggcagc
atgtgtcctt 180ttt 18311448DNAHomo sapiens 11aagaaggaga atccatttag
cacctcctca gcctggctca gtgattcata tgtggctttg 60ggaatacttg ggttttttct
gtttgtactc ttgggaatca cttctttgcc atctgttagc 120aatgcagtca
actggagaga gttccgattt gtccagtcca aactgggtta tttgaccctg
180atcttgtgta cagcccacac cctggtgtac ggtgggaaga gattcctcag
cccttcaaat 240ctcagatggt atcttcctgc agcctacgtg ttagggctta
tcattccttg cactgtgctg 300gtgatcaagt ttgtcctaat catgccatgt
gtagacaaca cccttacaag gatccgccag 360ggctgggaaa ggaactcaaa
acactagaaa aagcattgaa tggaaaatca atatttaaaa 420caaagttcaa
tttagctgga aaaaaaaa 44812401DNAHomo
sapiensmodified_base(11)..(11)a, c, t, g, unknown or other
12ggccgcggca nccgctacga cctggtcaac ctggcagtca agcaggtctt ggccanacaa
60gagccacctc tgggtgaagg aggaggtctg gcggatggag atctacctct ccctgggagt
120gctggccctc ggcacgttgt ccctgctggc cgtgacctca ctgccgtcca
ttgcaaactc 180gctcaactgg agggagttca gcttcgttca gtcctcactg
ggctttgtgg ccntcgtgct 240gagcacactn cacacgctca cctacggctg
gacccgcgcc ttcgaggaga gccgctacaa 300gttctacctn cctcccacct
tcacgntcac gctgctggtg ccctgcgttc gttcatcctg 360ggccaaagcc
ctgtttntac tgccttgcat tcagccgnag a 40113133PRTHomo
sapiensMOD_RES(4)..(4)Any amino acid 13Ala Ala Ala Xaa Ala Thr Thr
Trp Ser Thr Trp Gln Ser Ser Arg Ser1 5 10 15Trp Pro Xaa Lys Ser His
Leu Trp Val Lys Glu Glu Val Trp Arg Met 20 25 30Glu Ile Tyr Leu Ser
Leu Gly Val Leu Ala Leu Gly Thr Leu Ser Leu 35
40 45Leu Ala Val Thr Ser Leu Pro Ser Ile Ala Asn Ser Leu Asn Trp
Arg 50 55 60Glu Phe Ser Phe Val Gln Ser Ser Leu Gly Phe Val Ala Xaa
Val Leu65 70 75 80Ser Thr Leu His Thr Leu Thr Tyr Gly Trp Thr Arg
Ala Phe Glu Glu 85 90 95Ser Arg Tyr Lys Phe Tyr Leu Pro Pro Thr Phe
Thr Xaa Thr Leu Leu 100 105 110Val Pro Cys Val Arg Ser Ser Trp Ala
Lys Ala Leu Phe Xaa Leu Pro 115 120 125Cys Ile Gln Pro Xaa
1301424DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 14actttgttga tgaccaggat tgga 241524DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
15cagaacttca gcacacacag gaac 241623DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
16ttaggacaac ttgatcacca gca 231724DNAArtificial SequenceDescription
of Artificial Sequence Synthetic primer 17tgtccagtcc aaactgggtt
attt 241823DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 18agggagttca gcttcgttca gtc 231924DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
19ggtagaactt gtagcggctc tcct 242024DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
20gactgagctg gaactggaat ttgt 242124DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
21tttgaggaga cttcatctca ctgg 242214DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
22ttttgtacaa gctt 142344DNAArtificial SequenceDescription of
Artificial Sequence Synthetic oligonucleotide 23ctaatacgac
tcactatagg gctcgagcgg ccgcccgggc aggt 442410DNAArtificial
SequenceDescription of Artificial Sequence Synthetic
oligonucleotide 24acctgcccgg 102542DNAArtificial
SequenceDescription of Artificial Sequence Synthetic
oligonucleotide 25gtaatacgac tcactatagg gcagcgtggt cgcggccgag gt
42268DNAArtificial SequenceDescription of Artificial Sequence
Synthetic oligonucleotide 26acctcggc 82722DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
27ctaatacgac tcactatagg gc 222822DNAArtificial SequenceDescription
of Artificial Sequence Synthetic primer 28tcgagcggcc gcccgggcag gt
222920DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 29agcgtggtcg cggccgaggt 203015PRTHomo sapiens
30Tyr Gln Gln Val Gln Gln Asn Lys Glu Asp Ala Trp Ile Glu His1 5 10
153122DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 31acaagagcca cctctgggtg aa 223223DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
32agttgagcga gtttgcaatg gac 233325DNAArtificial SequenceDescription
of Artificial Sequence Synthetic primer 33atatcgccgc gctcgtcgtc
gacaa 253426DNAArtificial SequenceDescription of Artificial
Sequence Synthetic primer 34agccacacgc agctcattgt agaagg
263515PRTHomo sapiens 35Trp Lys Met Lys Pro Arg Arg Asn Leu Glu Glu
Asp Asp Tyr Leu1 5 10 15369PRTHomo sapiens 36Gly Leu Leu Ser Phe
Phe Phe Ala Val1 5379PRTHomo sapiens 37Phe Leu Tyr Thr Leu Leu Arg
Glu Val1 5389PRTHomo sapiens 38Leu Leu Leu Gly Thr Ile His Ala Leu1
5399PRTHomo sapiens 39Leu Ile Phe Lys Ser Ile Leu Phe Leu1
5409PRTHomo sapiens 40Met Leu Thr Arg Lys Gln Phe Gly Leu1
5419PRTHomo sapiens 41Phe Leu Tyr Ser Phe Val Arg Asp Val1
5429PRTHomo sapiens 42Ala Leu Leu Ile Ser Thr Phe His Val1
5439PRTHomo sapiens 43Leu Leu Ser Phe Phe Phe Ala Met Val1
5449PRTHomo sapiens 44Gly Leu Leu Ser Phe Phe Phe Ala Met1
5459PRTHomo sapiens 45Ser Leu Trp Asp Leu Arg His Leu Leu1
5466PRTArtificial SequenceDescription of Artificial Sequence
Synthetic 6xHis tag 46His His His His His His1 54715PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 47His
Ser Ser Lys Glu Lys Leu Arg Arg Glu Arg Ile Lys Tyr Cys1 5 10
154818DNAArtificial SequenceDescription of Artificial Sequence
Synthetic oligonucleotide 48tttttttttt tttttttt 18
* * * * *